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Abstract
The retinoblastoma tumor suppressor protein (pRB) functions through multiple
mechanisms to serve as a tumor suppressor. pRB has been well characterized to be
inactivated through phosphorylation by CDKs. pRB dephosphorylation and activation is
a much less characterized aspect of pRB function. In this thesis, I detail work to study the
post translational control of pRB phosphorylation. Here I present work detailing efforts
to generate a gene targeted mouse which disrupts PP1 binding to the C-terminus
of pRB, allowing for detailed study of the mechanisms of pRB dephosphorylation.
This work also details an examination of acetylation in the C-terminus of pRB, which
disrupts CDK phosphorylation of pRB. I generated a site specific antibody to examine
K873/K874 acetylation, and carried out characterization of this set of post-translational
modifications. This work highlights the complex mechanisms surrounding pRB
phosphorylation state and regulation of pRB activation.

Keywords: pRB, post-translational modifications, DNA damage, dephosphorylation,
acetylation, Protein Phosphatase 1, gene targeted mouse
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Chapter 1
Introduction

1

1.1
1.1.1

Classical Roles of pRB
pRB Regulates the G1 to S Transition of the Cell Cycle

The retinoblastoma tumor suppressor protein (pRB) was identified as the product of the
retinoblastoma susceptibility gene RB1, with mutations in this gene being the cause of
inherited cancers of the retina which are termed retinoblastomas (Friend et al., 1986; Lee
et al., 1987). pRB was classified as a tumor suppressor before it was apparent what the
biological function of this protein was through evaluation of the genetics of
retinoblastoma patients as well as study of oncogenic viruses (Dyson et al., 1989;
Knudson, 1971; Murphree and Benedict, 1984; Whyte et al., 1988). Initial functional
studies of pRB determined that pRB plays a critical role in regulating the cell cycle, by
controlling the progression of the cell from G1 into the S-phase (DeCaprio et al., 1989).
This regulation of the cell cycle is imparted through the regulation of a family of
transcription factors known as the E2Fs through a physical interaction (Chellappan et al.,
1991; Hiebert et al., 1992a; Lees et al., 1993) which was demonstrated to occur through
the “small pocket” domain (res. 379-792) and the C-terminus of pRB (res. 793 –
928)(Qin et al., 1992)(Fig. 1.1). The E2Fs induce a transcriptional program at the G1-S
transition that functions to drive the entry into S-phase and initiate DNA synthesis (Blake
and Azizkhan, 1989; Dalton, 1992; Hiebert et al., 1989; Thalmeier et al., 1989). The
expression of multiple different E2F family members is able to drive cells into S phase
(DeGregori et al., 1997; Johnson et al., 1993) highlighting the importance of the E2F
family in mediating the G1-S transition. The physical interaction though between pRB
and E2Fs was found to lead to negative regulation of E2F target genes (Helin et al., 1993;
Hiebert et al., 1992a), thus giving a mechanism to pRB‟s ability to regulate the G1-S
transition of the cell cycle and a basis for pRB‟s tumor suppressive properties.
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Figure 1.1: Structures of the Pocket Proteins
The pocket proteins are defined by the small pocket region consisting of the A and B
cyclin fold domains that are conserved across all three members. The LXCXE binding
cleft for LXCXE motif containing proteins is highly conserved across the pocket protein
family. pRB is primarily distinguished structurally from the other pocket proteins
members by a unique interaction with E2F1 in the C-terminus. The C-terminus of pRB
also contains overlapping binding sites for Cyclin-CDKs and PP1. The other pocket
protein family members, p107 and p130, are distinguished from pRB by the presence of a
Cyclin-CDK binding domain in the small pocket itself and an insert in the B part of the
small pocket. The N-terminus of p107 and p130 also contain a CDK inhibitory domain
which is unique to these two family members.
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1.1.2

The Pocket Protein Family

The pocket protein family consists of three highly related proteins, which are pRB, and
the gene products of RBL1 and RBL2, p107 and p130 (Fig. 1.1) (Cobrinik et al., 1993;
Ewen et al., 1991; Hannon et al., 1993; Mayol et al., 1993). Each family member
contains a highly conserved region called the “small pocket” which is made up of an A
and B domain consisting of single cyclin-like folds, which are separated by a flexible
linker region(Lee et al., 1998) (Fig 1.1). This domain serves as the minimal binding
domain of many viral oncoproteins(Hu et al., 1990) and is sufficient to repress
transcription through interactions with E2Fs (Chow et al., 1996; Chow and Dean, 1996;
Sellers et al., 1995). Viral oncoprotein binding to the small pocket has been attributed to
the LXCXE motif. Crystallography has demonstrated that the LXCXE motif contained in
viral oncoproteins makes contact with a shallow groove in the B domain of the small
pocket (Lee and Cho, 2002; Lee et al., 1998) known as the LXCXE binding cleft. The
small pocket, though being highly conserved across the family members and different
species, still has subtle differences between the different family members, with p107 and
p130 having insertions in the B domain and a longer linker relative to pRB(Classon and
Dyson, 2001; Hurford et al., 1997; Mulligan and Jacks, 1998). The “large pocket”
consists of the small pocket as well as the C-terminus and is the minimal growth
suppressing domain and is sufficient to interact with the E2F family of transcription
factors and inhibit E2F target gene transcription(Bremner et al., 1995; Hiebert, 1993;
Hiebert et al., 1992b; Qin et al., 1992; Yang et al., 2002). This interaction is mediated
through a physical association of the large pocket with the transactivation domain of the
E2F (Lee et al., 2002). Specific amino acids in the transactivation domain of E2F make
conserved contacts with amino acids in the A domain. Further contacts with the largely
unstructured C-terminus of the large pocket further act to stabilize this interaction with
E2Fs, leading to an inhibition of E2F transcriptional activity.

1.1.3

A Model of pRB and E2Fs at the G1-S Transition

pRB has been shown to be regulated in a cell cycle dependent manner and as mentioned
above to be a central regulator of the cell cycle(DeCaprio et al., 1989; Huang et al., 1988;
Takahashi et al., 1991). Pocket proteins, which lack intrinsic ability to bind DNA, bind to
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E2F family members, thus localizing themselves at E2F transcriptional target genes.
Pocket proteins though display different cell cycle roles due to differential expression and
preference for specific E2F family members (Classon and Dyson, 2001; Henley and
Dick, 2012). The localization of pocket proteins at E2F target genes thus enables active
repression of these genes and prevents progression into the cell cycle. Upon entrance to
the cell cycle, expression of the retinoblastoma protein increases and pRB localizes to
E2F target genes, inhibiting the transcriptional activity of E2Fs. This is mediated by
physically masking their transactivation domain as mentioned above, preventing
transcription of genes required for progression into S-phase(Hurford et al., 1997; Lavia
and Jansen-Durr, 1999; Takahashi et al., 2000). Activation of E2Fs, and progression into
S-phase, is mediated by phosphorylation of pocket proteins in a cell cycle-dependent
manner by cyclin/cyclin-dependent kinase (CDK) complexes. Mitogen stimulation of
cells leads to activation of CDK complexes and phosphorylation of the pocket proteins
(Buchkovich et al., 1989; DeCaprio et al., 1992; Lin et al., 1991; Mihara et al., 1989).
The phosphorylation of pocket proteins leads to a release of E2F binding, allowing for
the transactivation of E2F target genes (Burke et al., 2010; Chittenden et al., 1993;
Mudryj et al., 1991). The activation of CDK complexes occurs in a feed-forward loop
that is antagonized by CDK inhibitors (CKIs). As a result of a feed forward loop for CDK
complexes, phosphorylation of pocket proteins is maximized, and thus cells irreversibly
advance into S-phase (Fig 1.2)(Mittnacht, 1998; Sherr and Roberts, 1999; Sherr, 1994).

1.1.4

Regulation of Heterochromatin through LXCXE interactions
with Pocket Proteins

As mentioned above, pocket proteins contain a highly conserved region in the small
pocket that facilitates binding of viral oncoproteins, the LXCXE binding cleft. While
highly conserved in viral oncoproteins, this LXCXE motif also has been found to be
conserved with a host of cellular proteins and thus are able to bind in the LXCXE binding
cleft (Dick, 2007). The majority of the proteins that bind through the LXCXE binding
cleft function in the role of chromatin remodeling factors (CRFs), with notable
interactions including HDAC1 and Suv39h1(Brehm and Kouzarides, 1999; Brehm et al.,
1998; Nielsen et al., 2001). The association of these CRFs with pocket proteins allows for
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Figure 1.2: Model of pRB function in the Regulation of the G1-S transition of the
cell cycle
In G1 pRB interacts with the transactivation domain of E2F/DP heterodimer and blocks
their activation of E2F target genes. pRB-E2F-DP complexes bound to E2F target genes
are capable of recruiting chromatin remodeling factors (CRFs) to further repress the
activation of these genes through the generation of a repressive chromatin environment.
As cells transition through G1 into S phase, cyclin dependent kinases are activated. This
includes CDK4 and CDK6 with Cyclin D and CDK2 with Cyclin E. Cyclin/CDK
phosphorylation of pRB phosphorylation leads to the release of E2F/DP heterodimers,
allowing for active transcription of E2F target genes and progression of the cell into Sphase.
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recruitment of proteins that act to establish a repressive heterochromatin environment,
allowing for establishment of heterochromatin at E2F target genes which have a pocket
protein associated with them. This adds a further level of repression and regulation of
E2F target genes in regards to our model of the pRB/E2F G1-S transition presented in
Figure 1.2.
While CRFs are a predominant class of proteins that have interactions mediated
through the LXCXE binding cleft, other classes of proteins bind and act through LXCXE
interactions with pRB including those involved with DNA replication and
differentiation(Chan et al., 2001a; Dick, 2007; Miyake et al., 2000; Nguyen et al., 2004).
The preponderance of different protein complexes that interact with pRB through the
LXCXE binding cleft are important to control of cell proliferation, though not through
direct regulation of E2F target gene transcription as a gene targeted mouse developed in
our lab, the Rb1ΔLXCXE (Rb1ΔL), which ablates the LXCXE binding cleft in pRB, do
not have upregulated E2F target genes and are viable, fertile and born at nearly the
expected Mendelian ratios(Isaac et al., 2006). Mouse embryonic fibroblasts (MEFs) from
Rb1ΔL/ΔL mice though fail in properly establishing a full senescence program and seem to
be defective for binding to PML proteins which facilitate the senescence program(Talluri
and Dick, 2014; Talluri et al., 2009). Rb1ΔL/ΔL mice also exhibit defects in the ability to
respond to TGF-β signalling during breast development (Francis et al., 2009). From these
results, we can gather that a host of multimeric complexes centered on pRB/E2F
interactions exist and that the proper regulation of these interactions may be critical in
understanding pRB‟s ability to actively repress E2F target genes and lead to a stable cell
cycle arrest.

1.2
Post G1-S Roles of the Retinoblastoma Protein
are Tumor Suppressive
As mentioned above, the first regulatory paradigm discovered for pRB for regulation of
the cell cycle is in regards to its role in mediating the G1-S transition in the cell cycle.
Recent work in our lab and others have begun to discover other regulatory roles of pRB
beyond the G1-S transition that may contribute to the tumour suppressive functions of
pRB and appear to be unique to pRB alone.
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1.2.1

A pRB/E2F1 “Specific” Interaction that Exists Outside of G1

As described above, pRB acts to repress E2F transcription through a physical association
of the large pocket of pRB with the transactivation domain of E2Fs. Among the activator
E2Fs, E2F1 demonstrates unique and possibly conflicting functions in regards to the
other E2Fs. This is highlighted in a mouse genetic model where E2F1 has been ablated,
which leads to defective apoptosis in thymocytes resulting in a defect in negative
selection of T-cells (Field et al., 1996). This apoptotic defect is further highlighted as
mouse genetic models ablating other E2Fs fail to show similar defects in regards to
apoptosis (Chen et al., 2009; Humbert et al., 2000; Rempel et al., 2000). E2F1 induction
of apoptosis relies on an induction of p53 and a physical association with a host of proapoptotic genes including p73, Caspase 8, and Bid (Cao et al., 2004; Kowalik et al.,
1995; Nahle et al., 2002; Pediconi et al., 2003; Stanelle et al., 2002; Zhu et al., 1999).
pRB interestingly has been shown to be localized with E2F1 at these pro-apoptotic
promoters and localization of pRB and E2F1 across the genome during S-phase has been
demonstrated through ChiP experiments(Ianari et al., 2009; Wells et al., 2003). Thus
from overview of this data, pRB/E2F1 complexes seem to act in a unique manner relative
to the canonical description of pRB/E2F interactions described above.
Through mutational studies of the large pocket of pRB, it was found that E2F1alone was
able to bind to the C-terminus of pRB and that this interaction was unique within the
pocket protein family to pRB/E2F1(Dick and Dyson, 2003). This interaction was found
to be through distinct binding conformations with the C-terminus of pRB interacting with
the marked box domain of E2F1(Julian et al., 2008). This interaction of the pRB cterminus with the Marked box domain of E2F1 has been distinguished as the “Specific
site” interaction while the large pocket binding of pRB to E2F1-4 has been distinguished
as the “General site” (Fig 1.3). Interestingly, recent work has suggested that the specific
complex is resistant to two canonical methods of disrupting pRB binding to E2Fs, with
the viral oncoprotein E1A being unable to disrupt this complex (Seifried et al., 2008).
Furthermore, this specific interaction was demonstrated to be resistant to CDK
phosphorylation, allowing for a population of E2F1 to be bound by pRB even after
phosphorylation(Cecchini and Dick, 2011). Interestingly, this complex was demonstrated
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Figure 1.3: pRB has a Unique Interaction with E2F1
pRB is able to interact with E2F1 through two distinct interactions. The „General‟
interaction is shared by all E2Fs that bind to pRB. This involves the large pocket, (the
small pocket and the C-terminus), interacting with the transactivation domain of E2Fs.

The „Specific‟ interaction, which is unique for pRB among the pocket protein family, is
through residues 825-860 of the pRB C-terminus with the marked box domain of E2F1.
A -Cyclin A binding domain. DBD- DNA binding domain. DMZ- Dimerization domain.
MB- Marked box domain. TA- Transactivation domain.
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to be able to regulate the expression of p73 in vivo, and to modulate this response in the
context of DNA damage signaling potentially give a mechanism to explain the pro
apoptotic roles of pRB and E2F1 mentioned above(Carnevale et al., 2012; Julian et al.,
2008). With the emergence of a multiple unique pRB/E2F1 interaction surfaces that
appear to have functionally different consequences, understanding the regulation between
these two unique complexes presents an exciting area for deeper understanding of pRB
tumour suppressive functions.

1.2.2

LXCXE Interactions with pRB Beyond G1

As mentioned above, many classes of proteins bind to pRB through the LXCXE binding
cleft and help to facilitate a stable arrest in G1 of the cell cycle. As mentioned above, a
gene targeted mouse model developed in our lab, Rb1ΔL, are viable, though exhibit
defects in scenarios of cell cycle exit including senescence, response to γ-irradiation and
response to TGF-β signalling(Francis et al., 2009; Talluri et al., 2009). These mice,
though while not succumbing to spontaneous formation of cancer, interestingly exhibited
a form of genomic instability with an increase in aneuploidy (Isaac et al., 2006). From
this study, the aneuploidy that accumulated in Rb1ΔL MEFs was attributed to the fusions
in the pericentromere of chromatin leading to aberrant progression through mitosis. As
highlighted above, no defects in E2F target gene expression are observed in Rb1ΔL MEFs,
including E2F target genes involved in mitosis, including Mad2 and BubR1, which
compose the spindle checkpoint(Isaac et al., 2006). While direct effects related to E2F
transcription were ruled out, recent work from our lab, as well as other investigators have
revealed that pRB is able to interact with the Condensin II complex subunit Cap-D3 and
that this interaction is dependent on binding in the LXCXE cleft of pRB(Coschi et al.,
2010; Longworth et al., 2008; Manning et al., 2010). Interestingly this interaction was
able to mechanistically explain the earlier mentioned defects in pericentromeres of Rb1ΔL
MEFs and that proper regulation of this interaction is required for full pRB mediated
tumour suppression (Coschi et al., 2010). With these findings, an unknown determinant
of this mechanism is how in fact pRB localizes to the pericentromere without intrinsic
ability to bind DNA. Recent observations from our lab have determined that pRB
localization to the pericentromere of chromatin is dependent on pRB binding to E2F1
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leading to Condensin II complex recruitment at the pericentromeres (Coschi et al., 2014).
Furthermore, failure to recruit a complex of pRB/E2F1/Condensin II leads to an increase
in genomic instability due to replicative stress (Coschi et al., 2014)
With the evidence of LXCXE dependent interactions of pRB that persist beyond
G1 of the cell cycle, one question that persists is how this interaction is retained in an
LXCXE manner. Prior observations suggest that phosphorylation of pRB by CDKs while
disrupting pRB/E2F interactions through the general site also disrupt chromatin
remodelers from binding to the LXCXE binding cleft (Harbour et al., 1999a; Knudsen
and Wang, 1996). With these observations, speculation in the pRB field remains on how
the LXCXE dependent interactions with pRB persist past the G1 phase of the cell cycle
when pRB is extensively phosphorylated. By gaining a further understanding of the
control and regulation of pRB phosphorylation, this offers a potential means to regulate
and control these interactions.

1.3

Post-Translational Modifications of pRB

As described in the above mentioned sections, pRB plays host to numerous functions that
comprise the roles of pRB as a prototypical tumour suppressor. To understand the various
contrasting functions and interactions, it is necessary to further study the posttranslational modifications of pRB to offer potential insights into the control of these
different functions.

1.3.1

CDK Phosphorylation of pRB

As mentioned in previous sections, pRB has been observed to be phosphorylated by
Cyclin/CDK complexes upon mitogen stimulation. The initial characterization of CDK
phosphorylation of pRB was based on altered electrophoretic migration throughout the
cell cycle with the observation of two unique species of pRB with regards to
electrophoretic migration(Buchkovich et al., 1989). Through various biochemical and
mass spectrometry methods, 15 CDK sites have been identified on pRB (Fig 1.4)(Brown
et al., 1999; Connell-Crowley et al., 1997; Dephoure et al., 2008; Zarkowska and
Mittnacht, 1997). In early G1 of cycling cells or G0 in non-cycling cells, few of these
CDK sites are phosphorylated (Ezhevsky et al., 2001; Ezhevsky et al., 1997). This
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Figure 1.4: CDK Phosphorylation Sites and Lysine Acetylation Sites on pRB
pRB is extensively phosphorylated on CDK sites dispersed throughout the pRB primary
structure with 15 known CDK phosphorylation sites confirmed through various
biochemical and mass spectrometry means. Acetylation is found on both K873 and K874
in the C-terminus of pRB and is highlighted in purple. Acetylation has also been
demonstrated on other residues of pRB, indicated in orange, though these are primarily
only validated using mass spectrometry methods.
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species of lightly phosphorylated pRB has been termed the hypo-phosphorylated form of
pRB which is able to retain binding to E2Fs. These early phosphorylation events are
catalyzed by activation of Cyclin D-CDK4/6 complexes which interact through a docking
site in the C-terminus of pRB (Ezhevsky et al., 2001; Wallace and Ball, 2004). Following
these initial phosphorylation events, as the cell progresses towards S phase of the cell
cycle, activation of Cyclin E-CDK2 complexes leads to substantially more
phosphorylation of pRB(Harbour et al., 1999b). This species of substantially
phosphorylated pRB is characterized as the hyper-phosphorylated form of pRB and is
unable to bind E2Fs through the general interaction, though retaining specific E2F1
binding as mentioned previously. This body of highlighted work suggests two basic
structural conformations of pRB, that of the hypo-phosphorylated form and a
conformation for the hyper-phosphorylated form of pRB. This potentially simplistic view
of two pRB phosphorylated forms of functional consequence though has begun to be
challenged through the emergence of recent works which suggest this is an
oversimplification of pRB regulation by CDK phosphorylation. Highlighted below are
works first suggesting that specific CDK phosphorylation sites on pRB may in fact have
unique functional consequences in respect to pRB function and that the
hypophosphorylated form of pRB which has previously described as the active form of
pRB may in fact be attributed to a collection of mono-phosphorylated pRB isomers.
As pointed out above, pRB contains 15 CDK sites, and while initial work has
focused on the hypo and hyper-phosphorylated forms of pRB, data has begun to emerge
in regards to potential roles of single phosphorylation sites in regards to specific
regulation of pRB function. Initial work to characterize phosphorylation sites suggested
that the C-terminal phosphorylation sites were sufficient to disrupt pRB from E2Fs with
more recent x-ray crystallography studies of pRB C-terminus with E2F1/DP1 peptides
demonstrating a similar phenomenon(Chow et al., 1996; Knudsen and Wang, 1996;
Rubin et al., 2005). Similar studies though for the N-terminus of pRB suggest that CDK
sites in this region are also sufficient to disrupt pRB binding to E2Fs. A crystallography
study using the pRB N-terminus with the small pocket suggests that T373
phosphorylation leads to folding of the N-terminus into the small pocket in an allosteric
manner which may block both E2F and LXCXE cleft mediated interactions with
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pRB(Burke et al., 2012). Furthermore, phosphorylation sites in the linker region of the
small pocket have also been examined with interesting results. S612 has been suggested
to be phosphorylated in scenarios of DNA damage, and although this site has been
implicated as a CDK phosphorylation site, under this cellular context phosphorylation is
catalyzed by Chk1/2 and leads to retention of E2F1 binding(Inoue et al., 2007;
Zarkowska and Mittnacht, 1997). S608 which also lies in the linker region, using a
phospho-mimetic and crystallography was observed to disrupt binding of E2Fs to pRB
highlighting that two proximal phosphorylation sites may in fact have highly divergent
functional roles(Burke et al., 2012).
More recently, insights into pRB phosphorylation by CDKs have begun to emerge
that further gives credence to the idea that control and regulation of single
phosphorylation sites may control the regulation of different discrete pRB functions.
Through analysis using 2D gel electrophoresis, Narasimha and colleagues demonstrate
that in the G1 phase of the cell cycle, pRB persists in distinct isomers of the monophosphorylated form with 14 distinct mono-phosphorylated pRB isomers present
(Narasimha et al., 2014). It was noted that upon DNA damage, pRB remained in a monophosphorylated form which was mediated by CyclinD/CDK4/6 activity(Narasimha et al.,
2014). Finally the authors noted that upon terminal differentiation of myoblasts into
myotubules, pRB was uniquely present in an un-phosphorylated form(Narasimha et al.,
2014).
From the above highlighted works, a more elaborate model of pRB
phosphorylation begins to be elucidated wherein the simple model of hypo and hyperphosphorylated pRB can be expanded to envision a system of multiple simultaneously
existing species containing different arrangements of site specific phosphorylation. This
potential model though begins to ask the question of how this tightly regulated system of
distinct single phosphorylation population of unique pRB molecules is maintained in
such a manner. To answer this potential question requires a full understanding of
regulation of not only pRB phosphorylation but of pRB dephosphorylation which will be
discussed in more breadth below.
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1.3.2

Acetylation of pRB

pRB has been shown to be acetylated at K873/K874 in the C-terminus when bound by
the p300/CBP co-activator complex(Chan et al., 2001b). Acetylation of these two lysine
residues, which reside in a CDK docking site in the C-terminus of pRB, leads to a
reduction in pRB phosphorylation by CDKs(Chan and La Thangue, 2001; Lowe et al.,
2002; Wallace and Ball, 2004). Furthermore, acetylation of these two residues of pRB
occurs in the cellular context of DNA damage and this leads to the accumulation of
pRB/E2F1 complexes (Markham et al., 2006). These results suggest that pRB acetylation
at these two sites may be beneficial in contexts of cellular arrest. This idea is further
substantiated with the observations that pRB acetylation occurs in the cellular context of
differentiation. With the use of C2C12 myoblasts, it was observed that pCAF, the
p300/CBP associated factor, is recruited to pRB to acetylate K873/K874 and that this is
required for transactivation of MyoD and proper differentiation (Nguyen et al., 2004).
Similar effects were also observed for keratinocyte differentiation, with acetylation
defective mutants unable to promote differentiation but were able to arrest cells in a
SaOS2 arrest assay (Pickard et al., 2010).
The observations recognized previously though in the literature could in fact be
attributed to other acetylation sites on pRB, due to the lack of commercial site specific
antibodies available for acetyl K873/K874 pRB. Mass spectrometry and global
proteomics approaches have elucidated other less characterized acetylation sites on pRB
which could be responsible for the mechanistic observations which have been ascribed to
K873/K874 acetylation. A study by Choudhary and colleagues (Choudhary et al., 2009)
treated A549, Jurkat and MV4-11 human cell lines with HDAC inhibitors and performed
mass spectrometry analysis on lysates from these cells. From this study, the authors
determined that K427, K548, K640, K652, and K896 on pRB were found to be acetylated
in this context of HDAC inhibitor treated cells. Similar proteomic scale studies have
identified K925 in the C-terminus as being acetylated, again with human cell lines that
had been treated with HDAC inhibitors (Hornbeck et al., 2012). Less characterized
acetylation sites within pRB are highlighted in Figure 1.4, where we can observe sites of
acetylation throughout pRB. Interestingly, similar proteomic approaches were performed
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in hepatocellular carcinoma tissue isolated from patients and strikingly from this study,
only acetylation on K874 could be detected on pRB from these patient samples (Zhao et
al., 2010). These findings offer insights that acetylation of pRB may be sensitive to
context and cell type. The findings that K874 acetylation was present through mass
spectrometry of Hepatocellular carcinoma tissue samples without K873 acetylation, in
contrast to previous reports, highlights the potential for both acetyl K873/K874 to not be
present in combination.
These results suggest that pRB acetylation may play a role in regulating the
phosphorylation of pRB in contexts where stable cell cycle arrest is required such as in
the scenarios of DNA damage or in differentiation. The work highlighted above though
asks the general question of whether this is a widespread occurrence or limited to very
specialized scenarios. Furthermore, most work was performed under in vitro conditions
and thus does pRB acetylation play a functional consequence under physiological
conditions remains to be answered.

1.4

pRB Dephosphorylation

As discussed in section 1.3.1 detailing pRB phosphorylation by CDKs, an emerging
picture of highly regulated site specific phosphorylation is beginning to emerge with the
potential for each individual phosphorylation site regulating specific functions and
interactions of pRB. While the heavily studied role of pRB phosphorylation offers some
insights into this regulation, the much less characterized area of pRB dephosphorylation
offers an enticing means of regulating and controlling the distribution of specific pRB
mono-phosphorylated isomers that have been shown to exist.

1.4.1

Regulation of pRB Dephosphorylation in the Cell Cycle

In a normal cycling cell, pRB becomes hyper-phosphorylated in late G1 and exists in this
species until late in mitosis. In the transition between metaphase and anaphase, there is a
sharp decrease in the activity of CDKs that result from the degradation of cyclin B by the
anaphase-promoting complex (APC) (King et al., 1995). At this point, pRB is actively
dephosphorylated primarily by the enzyme complex of Protein Phosphatase 1 (PP1)
(Alberts et al., 1993; Ludlow et al., 1993). Evidence also exists that Protein Phosphatase
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2 A (PP2A) may also play a role in mitotic dephosphorylation of pRB(Alberts et al.,
1993). The end result of this targeted dephosphorylation of pRB is a re-establishment of a
large population of hypo-phosphorylated pRB which can then re-engage and repress
E2Fs (Fig 1.5).
From this work, pRB was determined to be actively dephosphorylated in anaphase
by primarily PP1 but many questions remain in regards to how this process is specifically
regulated. Both PP1 and PP2A typically reside in multimeric complexes and interestingly
multiple different regulatory subunits for both enzymes have been shown to physically
interact with pRB(Ceulemans and Bollen, 2004; Kolupaeva and Janssens, 2012).

1.4.2

Regulation of pRB Dephosphorylation in Conditions of
Cellular Stress

As shown above, pRB dephosphorylation is a tightly regulated and coordinated event in a
normal cell cycle context. Outside of this tightly ordered system of regulation, pRB can
also be actively dephosphorylated in cellular contexts of stress such as oxidative stress,
DNA damage and hypoxia. Once again, PP1 has been shown to play a major role in the
dephosphorylation of pRB in response to cell cycle arrests induced by DNA damage or
hypoxia (Dou and Lui, 1995; Krucher et al., 2006; Lentine et al., 2012). Upon DNA
damage PP1 is activated to promote the dephosphorylation of pRB to a hypophosphorylated state that can maintain the interaction with E2Fs and block their
transcriptional activity to mediate an acute arrest of the cell cycle. (Wang et al., 2001) In
addition protein phosphatase 2 also interacts with and dephosphorylates pRB in some
cellular contexts(Kolupaeva and Janssens, 2012). Thus the current understanding of pRB
dephosphorylation in response to cellular stresses illuminates the potential complexity of
regulating the various phosphorylation sites of pRB.

1.4.3

A Specific and Direct Interaction of PP1 with the C-Terminus
of pRB

As mentioned above, pRB dephosphorylation appears to be a tightly regulated cellular
program involving multiple different multimeric protein complexes. Previous studies
carried out by our lab in coordination with another group determined that the C-terminus
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Figure 1.5: pRB Functions Throughout the Cell Cycle
As more research emerges on pRB, a broader understanding is beginning to emerge of

pRB function outside of the G1-S transition of the cell cycle. As highlighted previously
in Fig 1.2, pRB has historically been considered to mediate the G1-S transition of the cell
cycle by controlling E2F target gene transcription. Emerging work also indicates the
pRB/E2F1 complexes persist beyond G1 of the cell cycle through the „Specific‟
interaction. A pRB LXCXE interaction with the Condensin II complex also persists
beyond G1 of the cell cycle and mediates chromosomal condensation of pericentromeres
at major satellite repeats. CKI- Cyclin Dependent Kinase Inhibitors.

18

of pRB contains a unique site that allows for direct interaction between PP1 and
pRB(Hirschi et al., 2010). Analysis of a crystal structure of the pRB870-882 C-terminus
peptide bound to the α isoform of the PP1 catalytic subunit indicates that pRB binding is
outside of the catalytic cleft of PP1. Furthermore, binding of pRB to PP1 occurs in a
similar manner and location to that of the interactions that commonly occur between PP1
targeting subunits and PP1, with the interactions being mediated by a “RVxF” motif. This
binding interaction and motif interestingly is not present in the other pocket protein
family members, p107 and p130, indicating that this is a unique mechanism of regulation
for pRB.
Intriguingly, the minimal binding domain of PP1 to pRB directly overlaps a
previously identified binding site for Cyclin-CDK complexes in the C-terminus, and that
binding of each of these complexes was competitive and mutually exclusive(Hirschi et
al.). Furthermore, maximal catalytic activity from both Cyclin-CDK and PP1 complexes
towards a pRB substrate were achieved when bound to the docking site in the Cterminus. As mentioned above, pRB is able to be acetylated at K873/K874, and previous
works suggest that acetylation at these sites is responsible for decreased CDK activity in
regards to a pRB substrate. Potentially acetylation at these sites may regulate binding and
access to the docking site, further adding a potential layer of regulation and complexity to
this mechanism.

1.5

Hypothesis and Objectives

As described above in the preceding sections of this chapter, while a large body of work
has been established on general regulation of pRB phosphorylation, little has been
explored in the regulation of pRB dephosphorylation and functional consequences of
selective phosphorylation of pRB in regards to CDK phosphorylation. I hypothesize that
the regulation of pRB dephosphorylation is critical in regulating pRB function and
activity. Furthermore, I hypothesize that acetylation of lysines 873 and 874 in the pRB Cterminus potentially could play a role in the regulation of pRB dephosphorylation. To set
up about trying to answer these questions regarding the regulation of pRB
dephosphorylation I have outlined two specific aims in this thesis to address this
question.
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In the first aim, I detail work on generating and characterizing an antibody that
recognizes pRB acetylation in the C-terminus on lysines 873 & 874 which sit directly
within previously known CDK and PP1 binding sites within pRB. I validated this
antibody and demonstrated that this antibody specifically recognized acetylation of
lysines 873/874 of pRB using in vitro acetylation assays. Using this antibody, I examined
the ability of pRB to be properly phosphorylated by CDK2. I then examined cellular
conditions suggested from previous works on pRB acetylation to enrich for this
modification and found no evidence using my antibody of the presence of acetylK873/K874 pRB under these outlined cellular conditions.
In the second aim, I present work to create a novel gene targeted mouse model of
pRB which is defective for binding of PP1 to the pRB C-terminus. This mouse model,
which I classify as the Rb1ΔPP1, would allow for a proper and discrete study of pRB
dephosphorylation by PP1 and the potential mechanistic insights of this unique
interaction with pRB. Through the attempt to generate this mouse model of pRb, I was
unable to obtain viable mESCs which contained our targeted allele.
The results I present in this thesis detail the generation and characterization of an
anti-acetyl pRB antibody and demonstrate limited functional impact of this specific posttranslational modification. Furthermore, I have outlined the attempt to generate a mouse
model for pRB which is deficient for dephosphorylation and have observed that this
model was unable to be created through conventional gene targeting approaches.
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Chapter 2
Methods

2

2.1

Plasmids

All plasmids used in this thesis are described in Table 2.1. psCodon1-GST-RBLP has
been previously reported (Cecchini and Dick, 2011). pBSKRB12KBSacI was a kind gift
from Jean Wang and has been previously been reported (Chau et al., 2002)

2.2
2.2.1

Plasmid Construction
psCodon1-GST-RBLP-K873/K874A

PCR conditions and primers discussed here are detailed in 2.3.2 and Table 2.2. pFAD228
plasmid was used as a PCR template for RB379 and FD155 primers. This PCR product
was isolated and digested with BamH1/EcoR1. This digested product was then ligated
into psCodon1-GST-pRB LP which had been digested with BamH1/EcoRI. This lead to
the insertion of a fragment of pRB containing K873/K874A mutations into a bacterial
GST expression vector.

2.2.2

pRBΔPP1 Targeting Vector Construction
A targeting vector was constructed that allows for introduction of the pRBΔPP1

mutation (R869F F870R) in exon 25 of the mouse Rb1 gene. A brief outline of the
targeting vector construction is detailed in Figure 2.1 and an overview of how the
construct facilitates recombination is provided in Figure 4.2. Our strategy for targeting
was adopted from a previously published method targeting a nearby region (Chau et al.,
2002). The pFAD326 Plasmid was constructed by Michael Thawites contained R869F
F870R mutations in Exon 25 along with an insertion of an EcoRI restriction enzyme site
in intron 24. A PGK-Neo cassette flanked by LoxP sites was inserted at a BglII site in
intron 25. The pBSKΔBH plasmid was created by Fred Dick with a bluescript vector
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Table 2.1 Description of Plasmids Used and Created
Plasmid

Genes

Name

encoded

psCodon1GST-RBLP

Obtained/
Expression

Resistance
Constructed

Stock
Number

GST, pRBLP

Bacterial

Fred Dick

Ampicillin

0526

Rb1

N/A

Paul Stafford*

Ampicillin

0683

Ampicillin

0684

pRBDeltaPP1
Targeting
Vector

pFAD326

Bacterial

pBSKRB12k

Michael
Thawites

Bacterial

Jean Wang

Ampicillin

0685

Bacterial

Fred Dick

Ampicillin

0686

Neomycin

Bacterial

Fred Dick

Rb1

Bacterial

Fred Dick

Mammalian

Fred Dick

Ampicillin

0220

Bacterial

Paul Stafford*

Ampicillin

0687

bSacI
pBSKΔBH
pBSKPGKNeoLox
2
pCRIIRb1ex24

pFAD228

psCodon1GST-RBLPK873/K874A

pRB
K873/K874A

pRB
K873/K874A

Ampicillin,
Neomycin

Ampicillin,
Kanamycin

0137

0523

35

(pBSK) modified to remove the BamHI and HindIII sites from the multiple cloning site.
A vector containing a 20 kb fragment of the 3‟ end of the Rb1 gene (pBSK-RB12kbSacI)
was digested with SacI to obtain a 12 kb fragment, which was then ligated into the
pBSKΔBH plasmid after a SacI digest, to make the pFAD321 plasmid. The 326 plasmid
and pFAD321 plasmids were then digested with BamHI/HindIII, and ligated together to
make the final targeting construct. The targeting construct was then maxi-prepped, and
sequenced to confirm exon and neo cassette sequences and restriction mapped to confirm
correct assembly.

2.3
2.3.1

PCR and Primers
PCR Conditions to Create GST-RB LP K873/K874A (GST
Expression)

Master Mix per Reaction:








9 µL H2O
1 µL Vent Polymerase Buffer
1 µL 2 mM dNTPs
1 µL 100 mM FD 155 Primer
1 µL 100 mM Rb379 Primer
1 µL Vent Polymerase
2 µL 200 ng/µL pFAD228

PCR Reaction Conditions:
1.
2.
3.
4.
5.
6.
7.

94°C 2 mins
94°C 30 secs
45°C 30 secs
72°C 2 mins 30 secs
Go to Step #2, 34 times
72°C 10 mins
4°C Indefinite
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Figure 2.1: Schematic of the Rb1ΔPP1 Targeting Construct
ΔPP1

Schematic detailing the construction of the Rb1

targeting construct. pBSK-

Rb12kbSacI was cut with SacI restriction enzyme and ligated into pBSKΔBH, a
bluescript plasmid which had BamHI and HindIII sites in the multiple cloning site
removed. This plasmid, pFAD321 was cut with BamHI and HindIII along with pFAD326
ΔPP1

and were ligated together to create the Rb1

targeting construct. B-BamHI, H-HindIII,

R-EcoRI, S-SacI, 25*-Exon 25 with ΔPP1 mutation, 25- Exon 25, 26-Exon 26, 27- Exon
27
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Table 2.2: List of Primers
Primer

Oligonucleotide sequence

Name

Rb379

FD155

GCGGGATCCGAAGAGGTGAATGTAATTC
CTCC
CGCGAATTCCTCATTTCTCTTCCTTGTTTG

Obtained/Constructed

Fred Dick

Fred Dick
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2.4

Antibody Generation and Purification

Antibody generation and purification was performed as previously described(Taya et al.,
2003). Synthetic peptides were generated against amino acids of the C-terminus of
human pRB through Covance Discovery and Translational Services Inc. These peptides
were 15 mer sequences (Residues 867-881) that flanked residues K873/K874 and were
either unmodified or synthesized with acetylation of K873/K874. Two rabbits were
immunized with the acetylated peptide following a standard 118 day protocol. The
animals were subjected to a 3 week cycle of antigen boosts and test bleeds were taken 10
days following the boosts. Serum from initial test bleeds was used for initial ELISA
screening to determine the specificity of the serum towards the modified epitope. Serum
was then purified for anti-acetyl K873/K874 pRB antibody in 5 mL batches using a twostep immunoaffinity column chromatography procedure. Acetyl K873/K874 pRB and
unmodified K873/K874 immunoaffinity columns were prepared using a NPPKPL-Ac-KAc-K-LRFDIEG peptide sequence used to immunize the rabbits along with an
unmodified NPPKPL-K-KLRFDIEG. Peptides were reduced by incubation with an
immobilized TCEP reducing gel (5 mL for 2.5 mg of peptide, Pierce) for 15 minutes at
room temperature in gravity flow columns (Biorad). Reduced peptides were eluted in 0.5
mL fractions and the fractions containing the highest peptide concentrations, as
determined by Bradford assay, were pooled and coupled to 4 mL each of Sulfolink
Coupling gel (Pierce). Non-specific binding sites on the gel were blocked with 50 mL Lcysteine HCL and washed with 1M NaCl.
Antibody purification then was carried out, first by clearing the serum of debris
by centrifugation at 4°C at 1660 × g for 10 minutes. The cleared serum was then passed
through the immunoaffinity column coupled with modified acetyl-K873/K874 pRB
peptide at 4°C with flow through being saved. The column was then washed with 25 mL
of 1X PBS at 4°C. Bound IgG then was eluted from the column through a two-step
process. Initially, 8 mL of 0.2M Glycine-HCl pH 2.5 was added to the column and 1 mL
fractions were collected in microfuge tubes containing 95µL of 1.5M Tris-HCl pH 8.8 to
immediately neutralize each fraction to ~ pH 7.3. Following this the second elution step
was carried out where 8 mL of 0.2M Glycine-HCl pH 1.9 was added to the column and 1
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mL fractions were collected into tubes containing 160µL of 1.5M Tris-HCl pH 8.8 to
immediately neutralize each fraction to ~ pH 7.3. To remove non-acetyl-K873/K873 pRB
antibodies, elution fractions containing IgG as determined by Bradford assay were loaded
into the column coupled with unmodified peptide. This column was then subjected to a
similar approach as described above for the modified column, wherein the flow through
from the PBS wash step was isolated. Following purification, both columns were washed
with 25 mL of 1X PBS at 4°C, then washed with 10 mL of 1X PBS with 0.05% Sodium
azide at 4°C and stored for future use at 4°C. Purified acetyl-K873/K874 pRB antibody
was dialyzed against 2L of 1xPBS and diluted with storage buffer (1xPBS, 20%
Glycerol, 0.05% Sodium azide and 100 µg/mL BSA), and aliquoted and stored at -20°C.

2.5

Enzyme Linked Immunosorbent Assay

ELISA was adapted from a previously described method for testing antibody
specificity(Taya et al., 2003). ELISA screening was performed to test the specificity of
acetyl-K873/K874 antibody toward acetyl K873/K874 pRB substrate. Synthetic peptides
from Covance Discovery and Translational Services generated for acetyl-lysine 873/874
and non-acetylated pRB were used in this subsequent assay. 0.3 µg of peptides (or TBS
in the negative control) were added in triplicate to the wells of a flat bottom 96 well plate
(Falcon). The plate was incubated for 5 hours at room temperature to adsorb the peptides
to the bottom of the wells after which the supernatant was removed and 50 µL of
Blocking buffer (1x PBS, 3% BSA) was added for 2 hours at room temperature. Wells
were washed 3 times in TBST after which 30 µL of a titration (1/10, 1/100, 1/1000,
1/10000, 1/100000, 1/1000000, 1/100000000 in blocking buffer) of either serum or
purified anti-acetyl K873/K874 antibody was added to the wells and incubated for 1 hour
at room temperature. Wells were then washed 5 times in TBST after which 30 µL of
1:10000 diluted goat-anti rabbit secondary antibody coupled to alkaline phosphatase
(Sigma) in blocking buffer was added to the wells for 1 hour at room temperature. The
plate was then washed 3 times with TBST, followed by the addition of 50 µL of Akaline
Phosphatase Yellow (para-Nitrophenylphosphate) Liquid Substrate system for ELISA
(Sigma). Colorimetric analysis was then performed by reading absorbance at 405 nm on
Wallac-Victor plate reader.
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2.6

Peptide SPOT Membrane Assay

Peptide arrays of the pRB C-terminal region for both mouse and human consisting of 122
and 123 15-mer peptides each consisting of a one amino acid overlap were synthesized in
the Li lab as spots on a nitrocellulose membrane (Reineke and Sabat, 2009). Peptide
sequences for both the mouse and human arrays are outlined in Table 2.3. To carry out
epitope characterization of the indicated pRB antibodies, the membrane was rehydrated
in 100% ethanol for 1 minute, then distilled water was added to 50% and the membrane
was incubated at room temperature for 15 minutes. The membrane then was washed in
distilled water 3 times for 15 minutes each followed by 3 washes with Tris buffered
saline-0.1% Tween20 (TBST- 20 mM Tris pH 7.5, 150 mM NaCl, 0.1% Tween20) for 10
minutes each. The membrane was then blocked for 3 hours at room temperature by
incubation in 5% non-fat milk TBST. The membrane was then washed 3 times for 10
minutes each in TBST and incubated with the indicated primary antibody. pRB rabbit
polyclonal M153 antibody (Santa Cruz) was diluted 1:500, pRB mouse hybridoma
monoclonal antibody RB4.1 was diluted 1:10 from culture supernatant, pRB rabbit
antibody generated in our lab against the final 15 amino acids of the human pRB
sequence C15 was diluted 1:500 and pRB Sheep antibody M136 generated in our lab
against the mouse C-terminus was diluted 1:500. All primary antibodies used were
diluted in 5% non-fat milk TBST. Following primary antibody treatment, the membrane
was blocked for 3 hours at room temperature with 5% non-fat milk TBST. The
membrane was then washed 3 times for 10 minutes with TBST and incubated with
peroxidase secondary antibody (anti-mouse for RB4.1, anti-rabbit for Santa Cruz M153
and C15, and anti-sheep for M136) at a 1:10000 dilution in 5% non-fat milk TBST. The
membrane was then washed 3 times for 10 minutes in TBST and developed using
chemiluminescence detection solution (0.1M Tris pH 8.5, 390 µM courmaric acid, 2.46
mM luminol, 0.02% H2O2) and exposure to Amersham hyperfilm (GE Healthcare).
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Table 2.3: List of Human and Mouse pRB Peptides for SPOT Array
Peptide #
1.
2.
3.
4.
5.
6
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.

Human Peptide
FPSSPLRIPGGNIYI
PSSPLRIPGGNIYIS
SSPLRIPGGNIYISP
SPLRIPGGNIYISPL
PLRIPGGNIYISPLK
LRIPGGNIYISPLKS
RIPGGNIYISPLKSP
IPGGNIYISPLKSPY
PGGNIYISPLKSPYK
GGNIYISPLKSPYKI
GNIYISPLKSPYKIS
NIYISPLKSPYKISE
IYISPLKSPYKISEG
YISPLKSPYKISEGL
ISPLKSPYKISEGLP
SPLKSPYKISEGLPT
PLKSPYKISEGLPTP
LKSPYKISEGLPTPT
KSPYKISEGLPTPTK
SPYKISEGLPTPTKM
PYKISEGLPTPTKMT
YKISEGLPTPTKMTP
KISEGLPTPTKMTPR
ISEGLPTPTKMTPRS
SEGLPTPTKMTPRSR
EGLPTPTKMTPRSRI
GLPTPTKMTPRSRIL
LPTPTKMTPRSRILV
PTPTKMTPRSRILVS
TPTKMTPRSRILVSI
PTKMTPRSRILVSIG
TKMTPRSRILVSIGE
KMTPRSRILVSIGES
MTPRSRILVSIGESF
TPRSRILVSIGESFG
PRSRILVSIGESFGT
RSRILVSIGESFGTS
SRILVSIGESFGTSE
RILVSIGESFGTSEK
ILVSIGESFGTSEKF
LVSIGESFGTSEKFQ
VSIGESFGTSEKFQK
SIGESFGTSEKFQKI
IGESFGTSEKFQKIN
GESFGTSEKFQKINQ

Mouse Peptide
SSSPLRIPGGNIYIS
SSPLRIPGGNIYISP
SPLRIPGGNIYISPL
PLRIPGGNIYISPLK
LRIPGGNIYISPLKS
RIPGGNIYISPLKSP
IPGGNIYISPLKSPY
PGGNIYISPLKSPYK
GGNIYISPLKSPYKI
GNIYISPLKSPYKIS
NIYISPLKSPYKISE
IYISPLKSPYKISEG
YISPLKSPYKISEGL
ISPLKSPYKISEGLP
SPLKSPYKISEGLPT
PLKSPYKISEGLPTP
LKSPYKISEGLPTPT
KSPYKISEGLPTPTK
SPYKISEGLPTPTKM
PYKISEGLPTPTKMT
YKISEGLPTPTKMTP
KISEGLPTPTKMTPR
ISEGLPTPTKMTPRS
SEGLPTPTKMTPRSR
EGLPTPTKMTPRSRI
GLPTPTKMTPRSRIL
LPTPTKMTPRSRILV
PTPTKMTPRSRILVS
TPTKMTPRSRILVSI
PTKMTPRSRILVSIG
TKMTPRSRILVSIGE
KMTPRSRILVSIGES
MTPRSRILVSIGESF
TPRSRILVSIGESFG
PRSRILVSIGESFGT
RSRILVSIGESFGTS
SRILVSIGESFGTSE
RILVSIGESFGTSEK
ILVSIGESFGTSEKF
LVSIGESFGTSEKFQ
VSIGESFGTSEKFQK
SIGESFGTSEKFQKI
IGESFGTSEKFQKIN
GESFGTSEKFQKINQ
ESFGTSEKFQKINQM
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Peptide #
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.

Human Peptide
ESFGTSEKFQKINQM
SFGTSEKFQKINQMV
FGTSEKFQKINQMVS
GTSEKFQKINQMVSN
TSEKFQKINQMVSNS
SEKFQKINQMVSNSD
EKFQKINQMVSNSDR
KFQKINQMVSNSDRV
FQKINQMVSNSDRVL
QKINQMVSNSDRVLK
KINQMVSNSDRVLKR
INQMVSNSDRVLKRS
NQMVSNSDRVLKRSA
QMVSNSDRVLKRSAE
MVSNSDRVLKRSAEG
VSNSDRVLKRSAEGS
SNSDRVLKRSAEGSN
NSDRVLKRSAEGSNP
SDRVLKRSAEGSNPP
DRVLKRSAEGSNPPK
RVLKRSAEGSNPPKP
VLKRSAEGSNPPKPL
LKRSAEGSNPPKPLK
KRSAEGSNPPKPLKK
RSAEGSNPPKPLKKL
SAEGSNPPKPLKKLR
AEGSNPPKPLKKLRF
EGSNPPKPLKKLRFD
GSNPPKPLKKLRFDI
SNPPKPLKKLRFDIE
NPPKPLKKLRFDIEG
PPKPLKKLRFDIEGS
PKPLKKLRFDIEGSD
KPLKKLRFDIEGSDE
PLKKLRFDIEGSDEA
LKKLRFDIEGSDEAD
KKLRFDIEGSDEADG
KLRFDIEGSDEADGS
LRFDIEGSDEADGSK
RFDIEGSDEADGSKH
FDIEGSDEADGSKHL
DIEGSDEADGSKHLP
IEGSDEADGSKHLPG
EGSDEADGSKHLPGE
GSDEADGSKHLPGES
SDEADGSKHLPGESK
DEADGSKHLPGESKF
EADGSKHLPGESKFQ
ADGSKHLPGESKFQQ

Mouse Peptide
SFGTSEKFQKINQMV
FGTSEKFQKINQMVS
GTSEKFQKINQMVSN
TSEKFQKINQMVSNS
SEKFQKINQMVSNSD
EKFQKINQMVSNSDR
KFQKINQMVSNSDRV
FQKINQMVSNSDRVL
QKINQMVSNSDRVLK
KINQMVSNSDRVLKR
INQMVSNSDRVLKRS
NQMVSNSDRVLKRSA
QMVSNSDRVLKRSAE
MVSNSDRVLKRSAEG
VSNSDRVLKRSAEGG
SNSDRVLKRSAEGGN
NSDRVLKRSAEGGNP
SDRVLKRSAEGGNPP
DRVLKRSAEGGNPPK
RVLKRSAEGGNPPKP
VLKRSAEGGNPPKPL
LKRSAEGGNPPKPLK
KRSAEGGNPPKPLKK
RSAEGGNPPKPLKKL
SAEGGNPPKPLKKLR
AEGGNPPKPLKKLRF
EGGNPPKPLKKLRFD
GGNPPKPLKKLRFDI
GNPPKPLKKLRFDIE
NPPKPLKKLRFDIEG
PPKPLKKLRFDIEGA
PKPLKKLRFDIEGAD
KPLKKLRFDIEGADE
PLKKLRFDIEGADEA
LKKLRFDIEGADEAD
KKLRFDIEGADEADG
KLRFDIEGADEADGS
LRFDIEGADEADGSK
RFDIEGADEADGSKH
FDIEGADEADGSKHL
DIEGADEADGSKHLP
IEGADEADGSKHLPA
EGADEADGSKHLPAE
GADEADGSKHLPAES
ADEADGSKHLPAESK
DEADGSKHLPAESKF
EADGSKHLPAESKFQ
ADGSKHLPAESKFQQ
DGSKHLPAESKFQQK
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Peptide #
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.

Human Peptide
DGSKHLPGESKFQQK
GSKHLPGESKFQQKL
SKHLPGESKFQQKLA
KHLPGESKFQQKLAE
HLPGESKFQQKLAEM
LPGESKFQQKLAEMT
PGESKFQQKLAEMTS
GESKFQQKLAEMTST
ESKFQQKLAEMTSTR
SKFQQKLAEMTSTRT
KFQQKLAEMTSTRTR
FQQKLAEMTSTRTRM
QQKLAEMTSTRTRMQ
QKLAEMTSTRTRMQK
KLAEMTSTRTRMQKQ
LAEMTSTRTRMQKQK
AEMTSTRTRMQKQKM
EMTSTRTRMQKQKMN
MTSTRTRMQKQKMND
TSTRTRMQKQKMNDS
STRTRMQKQKMNDSM
TRTRMQKQKMNDSMD
RTRMQKQKMNDSMDT
TRMQKQKMNDSMDTS
RMQKQKMNDSMDTSN
MQKQKMNDSMDTSNK
QKQKMNDSMDTSNKE
KQKMNDSMDTSNKEE
QKMNDSMDTSNKEEK

Mouse Peptide
GSKHLPAESKFQQKL
SKHLPAESKFQQKLA
KHLPAESKFQQKLAE
HLPAESKFQQKLAEM
LPAESKFQQKLAEMT
PAESKFQQKLAEMTS
AESKFQQKLAEMTST
ESKFQQKLAEMTSTR
SKFQQKLAEMTSTRT
KFQQKLAEMTSTRTR
FQQKLAEMTSTRTRM
QQKLAEMTSTRTRMQ
QKLAEMTSTRTRMQK
KLAEMTSTRTRMQKQ
LAEMTSTRTRMQKQR
AEMTSTRTRMQKQRM
EMTSTRTRMQKQRMN
MTSTRTRMQKQRMNE
TSTRTRMQKQRMNES
STRTRMQKQRMNESK
TRTRMQKQRMNESKD
RTRMQKQRMNESKDV
TRMQKQRMNESKDVS
RMQKQRMNESKDVSN
MQKQRMNESKDVSNK
QKQRMNESKDVSNKE
KQRMNESKDVSNKEE
QRMNESKDVSNKEEK
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2.7

Cell Culture

C33A human cervical carcinoma cells were obtained from the American Type Culture
Collection (ATCC). Cells were thawed from stocks stored at -150°C and plated onto
10cm plates cultured in Dulbecco‟s Modified Eagle Medium (DMEM) supplemented
with penicillin (100U/mL), L-glutamate (2 mM), streptomycin (50 µg/mL) and 10% fetal
bovine serum (FBS). Cells were grown in a humidified incubator at 37°C with 5% CO2.

2.8

Recombinant Protein Purification

Recombinant GST Protein purification was performed as previously described(Cecchini
and Dick, 2011). Recombinant Proteins used for downstream applications were generated
using the following protocol. Plasmids encoding the desired recombinant protein were
transformed into competent BL21 Gold E.coli cells and plated onto 10 cm dishes
containing LB growth media with agar and supplemented with ampicillin (100 µg/mL)
and incubated for 16hrs at 37°C. Single colonies were isolated and grown in 25 mL of LB
media supplemented with 100 µg/mL ampicillin and grown for 16 hrs at 37°C shaking at
200 RPM in a C-24 New Brunswick Orbital Shaker. Cultures were transferred to 1 L of
LB media supplemented with 100 µg/mL ampicillin and grown for 4hrs at 25°C shaking
at 200 RPM. Cultures were then induced with 100 µM IPTG and were transferred to a
16°C incubator and left shaking at 200 RPM for 16 hrs in a G-25 New Brunswick Shaker.
Cell cultures were then centrifuged at 1660 × g for 45 min at 4°C to pellet cells. Cell
pellets were then either stored at -80°C or purification was performed immediately.
Cell pellets (either fresh or frozen) were washed with 1X Phosphate Buffererd
Saline (PBS) and then suspended in GST Lysis Buffer (20 mM Tris pH 7.5, 0.5 M NaCl,
0.5 mM EDTA, 10% Glycerol, 0.5% NP-40, 20 mM DTT and 0.25 mM PMSF).
Suspended cell pellets were subsequently sonicated at amplitude 3 with a 20 sec pulse 3
times. Cellular debris was then pelleted by centrifugation at 1660 × g for 30 mins at 4°C
and supernatant was isolated. The supernatant was then combined with 50% slurry of
glutathione-sepharose beads (GE healthcare) and then rocked for 1hr at 4°C. Glutathione
beads were subsequently centrifuged at 106 × g, 4°C for 2 mins with the resulting
supernatant removed and then washed 3 times with High Salt GST Lysis Buffer ( 20 mM
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Tris pH 7.5, 1 M NaCl, 0.5 mM EDTA, 10% Glycerol, 1% NP-40, 20 mM DTT and 0.25
mM PMSF). The beads were then washed 5 times with lysis buffer and finally washed
once with KCL Buffer (20 mM Tris pH 7.5, 0.1 M KCl, 10% Glycerol, 0.02% NP-40, 20
mM DTT and 0.25 mM PMSF. GST tagged recombinant proteins were then eluted from
Glutathione beads with the addition of 500 µL of GST Elution Buffer (50 mM Tris pH
8.0, 0.1M KCl, 0.1 mM EDTA, 10% Glycerol, 0.02% NP-40, 20 mM DTT, 0.25 mM
PMSF and 200 mM Glutathione) for 1 hr rocking at 4°C. Beads were then centrifuged at
106 × g for 5 mins at 4°C and supernatant was dialyzed against 1000x excess KCL buffer
at 4°C for 16 hrs. Protein samples were then aliquoted, snap frozen and stored at -80°C
until required for use.

2.9

GST Pulldown Binding Experiments

Recombinantly produced proteins were used for these assays and this procedure is
detailed above in 2.8. This procedure was carried out as previously reported (Dick et al.,
2000). In general 20 µL of Glutathione-sepharose beads were washed with 400 µL of
Low Salt GSE Buffer (20 mM Tris pH 7.5, 200 mM NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 1 mM DTT and 0.1% NP-40) twice before being centrifuged at 106 × g, 4°C
3mins. The beads were then suspended in 400 µL Low Salt GSE Buffer and 200 µg of
cell extract was added along with 3 µg of the desired GST tagged recombinant protein.
This mix was then rocked for 1 hr at 4°C and subsequently washed with twice with Low
Salt GSE Buffer. Beads were then resuspended 100 µL of 1X SDS-PAGE sample Buffer
(62.5 mM Tris pH 6.8, 10% Glycerol, 2% SDS, 72.5 mM β-ME and Bromophenol Blue)
and boiled for 5 mins at 95°C. Beads subsequently were centrifuged at 20800 × g for 1
min and supernatant was loaded on SDS-PAGE gel of indicated percentage for optimal
resolution for Western blotting and GST protein loading quantification.

2.10

Western Blotting and Immunoprecipitations

Western Blotting was used to determine protein abundance in samples and has
been previously described (Cecchini and Dick, 2011). In general, protein samples were
electrophoresed on 8% polyacrylamide gels unless otherwise stated. Gels were run in 1X
SDS-PAGE running buffer (25 µM Tris Base, 200 µM Glycine and 0.1% SDS) at 150-
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200 volts using a Biorad PowerPac HC 250 V to achieve proper resolution of desired
protein targets. Proteins were then transferred onto a nitrocellulose membrane (GE
Amersham Hybrid ECL) for 1hr on ice at 100 V in 1X Western Blot transfer buffer (48
µM Tris Base, 368 µM Glycine, 0.1% SDS and 20% Methanol). Membranes were then
blocked in 1X TBST (20mM Tris pH7.5, 150 mM NaCl and 0.1% Tween-20) with 3%
skim milk powder for 1hr rocking at room temperature. Membranes were then treated
with primary antibody solution in 1x TBST with 3% skim milk powder at indicated
working dilutions described below, overnight rocking at 4°C. Membranes were
subsequently washed 3 times for 10 mins with 1X TBST and then treated with secondary
antibodies of indicated species conjugated to HRP diluted 1:2000 in 1X TBST with 3%
skim milk. Membranes were left shaking for 1hr at 25°C before being washed 3 times for
10 mins with 1X TBST. Membranes were incubated with ECL solution (Supersignal
West Dura Extended Duration Substrate, Thermo Scientific) sufficient to properly cover
membrane for 2 mins. Membranes were then developed using ChemiDoc apparatus
(BioRad) with ImageLab software (BioRad) to achieve proper exposure for indicated
proteins.

2.11

In Vitro Acetylation Assay

GST-pRBLP recombinant proteins were used for this assay and were produced as
described above in 2.8. This method was adapted from previously reported methods
(Avvakumov et al., 2003; Kuninger et al., 2007). 3.5 µg of recombinant protein were
added to Acetylation Buffer (50 mM Tris pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.1%
NP-40, 1 mM PMSF, 1 mM DTT), with 10 µM of acetyl-CoA and the volumes were
made up to 20 µL with Acetylation buffer. Indicated reactions were then supplied 1 µg of
recombinant pCAF HAT domain (Cayman Chemicals) to act as the acetyltransferase.
Acetylation reactions were carried out for 10 mins at 30°C on a rotating platform.
Following this, samples were snap frozen to be used in downstream assays or the
reactions were stopped with the addition of SDS-PAGE sample buffer and
electrophoresed on 8% polyacrylamide gels.
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Table 2.4: Description of Antibodies
Antibody
Epitope

Species

Supplier / Source

Application

RB4.1

pRB

Mouse

Hybridoma

WB, IP

M153

pRB

Rabbit

Santa Cruz (sc-7905)

WB, IP

Rabbit

Paul Stafford*

WB, IP

Name

K873/K874
Ac-pRB
ac-pRB
4G12

Ac-Lysine

Mouse

Millipore

WB

M136

pRB

Sheep

Dick Lab/Michael Thwaites

IP

07-631

CDK2

Rabbit

Upstate

IP

C15

pRB

Rabbit

Dick Lab

WB
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2.12

In Vitro Kinase Assay

The CDK2 in vitro kinase assay was carried out according to a previously described
method (Forristal et al., 2014). Nuclear extracts from proliferating C33A cells were
collected as described above. 100 µg of extract was then added to 50 µL of Protein G
dynabeads pre-bound with 4 µg of rabbit IgG or 4 µg of α-CDK2 for 1.5 hrs at 4°C. The
beads were then washed twice in Kinase buffer (50 mM Tris pH 7.5, 10 mM MgCl2 and 1
mM DTT). Washed beads were subsequently resuspended in 30 µL of Kinase buffer, 1
µL of γ-ATP32 (10 µCi), 2 µg of recombinant GST-pRBLP and the volume was made up
to50 µL with Kinase buffer. The kinase reaction was carried out for 20 mins at 30°C and
then stopped with the addition of 5x Laemmli SDS Page Buffer. Samples were then
electrophoresed on 8% polyacrylamide gels and stained with Coomassie brilliant blue
solution to resolve protein bands. The gels were then dried and imaged to allow for
comparison of protein loading. The gel was then exposed to Amersham Hyperfilm MP
(GE healthcare) for proper resolution of radiolabelled substrates and autoradiography was
performed.

2.13

Immunopurified-Kinase Assay

Recombinant GST-pRB LP was prepared as discussed above in 2.8. Acetylated GSTpRB LP was prepared as described in 2.11. CDK2 was immunoprecipitated from
proliferating C33A cells using 4 µg of α-CDK2 antibody (Upstate) or rabbit IgG that had
been prebound by rocking with protein G dynabeads (Invitrogen) at 4°C for 1 hour. 6 µg
of acetyl-K873/K874 antibody and M136 antibody which had been purified against the
unmodified peptide discussed in 2.11, were prebound to protein G dynabeads for 1 hour
rocking at 4°C. 5.5 µg of either modified or unmodified GST-pRB LP protein or GST
was added to each IP for 1 hour rocking at 4°C. Each set of IPs was washed twice with
Kinase buffer (50 mM Tris pH 7.5, 10 mM MgCl2 and 1 mM DTT). CDK2 IP beads
were resuspended in 30 µL of Kinase buffer and combined with acetyl K873/K874 pRB
or unmodified pRB IP beads which had been resuspended with 30 µL of Kinase buffer,
with 12 µL added to the kinase reaction. 1 µL of γ-ATP32 (10 µCi) was added to each
reaction and the final volume was brought up to 50 µL with the addition of Kinase buffer.
Kinase reactions were then carried out as described in 2.9. 12 µL of each IP acetyl-
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K873/K874 pRB or unmodified pRB IP was set aside for Western blot analysis as
described above.

2.14

mESC Cell Culture

Cell culture for mESCs was performed to standard protocols as previously described
(Sicinski et al., 1995). mESCs were cultured in DMEM media with 4500 mg/L Glucose,
2 mM glutamine, 0.1 mM Non-Essential amino acids (Gibco #11140-050), 0.1 mM βmercaptoethanol (Sigma M7522) diluted in PBS, Leukemia Inhibitory Factor (LIF,
Millipore, ESG1106) 105 Units/L media, 50 µg/mL G418 (Sigma SLBB2604) and 15%
Fetal Bovine Serum (FBS). mESCs were cultured on plates coated with 0.1% gelatin
solution (Swine skin type II, Sigma G2500) with mitomycin c treated MEFs which were
plated the night before and left at 37°C to adhere to the gelatin coated plate. The mESCs
were grown in a humidified incubator at 37°C with 5% CO2 and sub-cultured until
optimal density was reached on a 10 cm dish. Cells were trypsinized with 0.25%
Trypsin/0.04% EDTA (GIBCO) with media being changed 1 hour prior to treatment with
trypsin.

2.15

Southern Blot Screening

The targeting construct was linearized by a NotI digestion, and provided to the London
Regional Transgenic and Gene Targeting facility where mouse embryonic stem cells
(mESCs) were electroporated and grown in neomycin selection medium. Southern blot
screening of mESCs was carried out as previously reported (Cecchini et al., 2014; Isaac
et al., 2006). Electroporated mESCs were selected and underwent clonal expansion onto
24 well culture plates. Cells were lysed in Tail Lysis Buffer (50 mM Tris pH 8.0, 100
mM NaCl, 0.1% SDS, 0.1 mM EDTA) with 200 µg/µL of Prot K overnight at 37°C.
Genomic DNA was then isolated through phenol chloroform extraction and quantified
using a nanodrop. 10 µg of DNA was digested overnight at 37°C with 20 units of the
desired restriction enzyme. The next morning, restriction digests were spiked with 20
units of restriction enzyme and left to digest at 37°C for 8 hours. Digested genomic DNA
was then electrophoresed in a 0.8% agarose gel without Ethidium bromide (EtBr)
overnight at 20V. The agarose gel was then stained in a TAE (40 mM Tris acetate, 1mM
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EDTA, pH 8.2) with Ethidium Bromide and visualized to determine migration distances
of the ladder and presence of digested DNA in the lanes. The gel was then washed 2
times for 30 minutes each shaking at room temperature in Wash Buffer 1 (1.5M NaCl,
0.5M NaOH). Following this the gel was washed for 5 minutes in Milli-Q water and then
the gel was washed 2 times for 30 minutes each shaking at room temperature in Wash
Buffer 2 (1 M Ammonium acetate, 20 mM NaOH). The gel was then placed in a
Stratagene Posiblot apparatus and the transfer was carried out overnight at room
temperature onto a nitrocellulose membrane (GE NitroPure 45 micron nitrocellulose
membrane). The membrane was then dried at room temperature for 1 hour and then
baked at 80°C for 1 hour. The membrane was then rehydrated with Hybridization Buffer
(0.2% SDS, 25 mM Na3PO4, 0.1% Sodium pyrophosphate, 4 mM EDTA, 8 mM Tris
Base, 600 mM NaCl, 0.2% Ficoll 400, 0.2% polyvinylpyrrolidone , 0.2% Bovine serum
albumin), placed in a glass cylinder and rotated at 65°C for 2 hours. During this time, the
indicated probe was labelled and quantified as discussed below in 2.15.1. The
hybridization buffer then was changed and fresh buffer was added with 1,000,000 CPM
of 32P-α dCTP labelled probe per mL of hybridization buffer. The membrane was left to
incubate with probe while rotating overnight at 65°C. The next day the membrane was
washed 3 times for 10 minutes at room temperature with Low Stringency Buffer (0.1%
SDS, 300 mM NaCl, 30 mM Sodium Citrate pH 7.0). The membrane then was washed 3
times for 10 minutes each at 65°C with High Stringency Buffer (0.1% SDS, 30 mM
NaCl, 3 mM Sodium Citrate pH 7.0). The membrane then was exposed to Amersham
hyperfilm (GE Healthcare) for autoradiography.

2.15.1

Southern Blot: Labeling and Purifying the Probe

Reactions are scaled for 25 ng of extracted probe DNA but can be scaled up as needed.
Labeling Reaction: Using Agilent Prime-It II Random Primer Labeling Kit (Agilent,
300385) contents
25 ng of DNA
10 µL Random Primers
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Add H2O up to 34 µL
5 min @ 95°C
Then Add:
10 µL 5x dCTP buffer
5 µL of 32P-α dCTP
1 µL Klenow
Place in 37°C water bath for 30 mins
Purifying the Probe:
Fill a 3 mL syringe with glass wool to 1 mL mark, being careful not to tightly pack the
wool
Add Sephadex G-50 Beads suspended in TE buffer to the top of the glass wool to 1.5 mL
mark, making sure beads are even over the wool
Centrifuged column at 210 × g for 1 minute and check levels and quality of sephadex
layer. Add more and centrifuge as needed.
Add labeled probe to column with 100 µL volume max/column, centrifuge (210 × g, 1
min) syringe in a conical tube and collect flow through which is labeled probe.
Add 10 µg sheared of salmon sperm DNA per 100 µL of flow through
Heat for 5 mins at 95°C, quantify activity of the probe by liquid scintillation.
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Chapter 3

3

Study of pRB K873/K874 Acetylation
3.1
Analysis of pRB Antibody Specificity in the pRB CTerminus

To study post-translational modifications of the pRB C-terminus, a comprehensive
understanding of epitope locations for antibodies that will be used for Western blotting
and immunoprecipitations (IPs) is critical for interpreting these results. As mentioned
above in the introduction, a specific portion of the pRB C-terminus is of interest to my
research due to the presence of the PP1 and CDK docking site, and the presence of the
K873/K874 residues that have been demonstrated to be acetylated. To study this region
of pRB, we mapped epitopes for the antibodies that we commonly use. The antibodies
that I examined for analysis were the following; mouse monoclonal hybridoma RB4.1,
rabbit polyclonal pRB antibody M153 from Santa Cruz, pRB rabbit antibody C15
generated in our lab against the final 15 amino acids of the human pRB C-terminus and a
sheep pRB antibody M136 generated against the 136 amino acids of the mouse pRB Cterminus.
To map epitopes of the various pRB antibodies available, I performed a peptide
SPOT assay. This consisted of an array of 122 or 123 peptides of the mouse and human
pRB C-terminal regions respectively. Each peptide is 15 amino acids long and each had a
one amino acid difference from its neighbour providing full coverage of all the 15 amino
acid peptides possible from the C-terminus of pRB. With these peptides spanning the
entire C-terminus, I incubated the membrane with each of the indicated antibodies and
visualized the membranes using standard western blotting procedures. From this analysis
for each respective antibody, specific epitopes or regions of preferred binding were
observed for each antibody. For RB4.1, I observed from the spot pattern depicted in Fig
3.1A that the epitope for this antibody corresponds to amino acids 822-836 in the human
sequence and 815-830 in the mouse sequence, which is illustrated in Fig 3.2A. For the
pRB C15 antibody, I observed from the peptide array in Fig 3.1B that binding could be
attributed to the C-terminus encompassing amino acids 908 to 928 in the human
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sequence. It was also observed that it was bound to one mouse peptide as shown in Fig.
3.1B, with this peptide corresponding to amino acids 906-920 in the mouse pRB Cterminus. Presented in Fig 3.2B is a schematic detailing C15 binding to human pRB Cterminus corresponding to residues 908-928 and binding in the mouse pRB C-terminus,
corresponding to residues 906-920. Both polyclonal antibodies exhibited widespread
binding throughout the C-terminus but did have regions of preference. From analysis of
the array presented in Fig 3.1C for M153, we observed peptides that were recognized
specifically. Detailed in Fig 3.2C in a diagram of the pRB C-terminus is the regions of
binding I observed for M153. While it is important to note that binding was observed in
regions encompassing the PP1-CDK docking sites as well as acetylation sites
K873/K874, many other prominent epitopes existed in the C-terminus including strong
epitopes in the early C-terminus. Through analysis of the array presented in Fig 3.1D for
M136, we again observed that there was a wide swath of binding throughout the Cterminus of pRB with epitopes encompassing the PP1-CDK docking site and K873/K874
acetylation sites. The epitopes for M136 were more concentrated on this region and
displayed minimal binding to the early portion of the pRB C-terminus.

3.2
Generation and Characterization of Anti-Acetyl
K873/K874 pRB Antibodies
As described in my introduction, the pRB protein has been shown to be acetylated in the
C-terminus on lysine residues 873 and 874 (Chan et al., 2001). This acetylation has been
shown to occur within a region of pRB that contains binding motifs for Cyclin-CDK
complexes as well as PP1 (Hirschi et al., 2010), thus the potential exists that these
modifications may act in a regulatory manner to control CDK phosphorylation or PP1
dephosphorylation of pRB. Though these post-translational modifications of pRB present
a unique and exciting means of regulation of pRB, no commercially available antibodies
exist for any combination of K873/K874 acetylation. Therefore, to further characterize
pRB K873/K874 acetylation and the potential regulatory nature of these posttranslational modifications, we set out to create an antibody that was specific for these
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Figure 3.1: Characterization of pRB Antibodies
A) Peptide spot membrane of human and mouse pRB assayed for mouse derived
monoclonal antibody RB4.1 epitopes. Peptides which demonstrated reactivity are
indicated by their peptide number. B) Peptide spot membrane of human and mouse pRB
probed with a rabbit antibody generated in our lab against the 15 C-terminal amino acids
of human pRB. C) Peptide spot membrane of human and mouse pRB for rabbit derived
polyclonal antibody M153 from Santa Cruz. D) Peptide spot membrane of human and
mouse pRB probed with a goat antibody generated in our lab against the C-terminal 136
amino acids of mouse pRB. N=1 for all peptide arrays
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Figure 3.2: Schematic of pRB Antibody Epitopes on Human and Mouse pRB
A) Schematic detailing the regions in the pRB C-terminus that demonstrated epitopes for
mouse hybridoma antibody RB4.1. B) Schematic detailing the epitope in the pRB human
C-terminus for rabbit pRB antibody C15. C) Schematic detailing the epitopes in the pRB
C-terminus for rabbit polyclonal antibody M153 from Santa Cruz. D) Schematic
detailing the epitopes in the pRB C-terminus for sheep polyclonal antibody M136
developed in the Dick Lab
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modifications. This process is outlined in the illustration presented in Figure 3.3A.
Covance Research Products Inc. was contracted to make an antibody that was able to
specifically detect acetyl-K873/K874. Two rabbits were immunized with a 15 amino acid
acetylated peptide that surrounded K873/K874 (NPPKPL-Ac-K-Ac-K-LRFDIEG)
following a standard 118 day protocol. The animals were subjected to a 3 week cycle of
antigen boosts and test bleeds were taken 10 days following the boosts. From the initial
test bleeds, Enzyme linked immunosorbent assays (ELISA) was carried out to test serum
for antibody production and response against both a synthetically modified peptide versus
an unmodified peptide, which are depicted in Figure 3.3B. Presented in Figure 3.4A is
quantification of these experiments, where we can see that serum was able to elicit a
significant response against both acetylated and unmodified peptide when compared to
the negative control through the use of statistical analysis at the half maximal absorbance
dilution. Through statistical analysis, no significant difference was observed for the
unmodified versus the acetylated peptide. With this result, this encouraged us to continue
production of serum and to begin purification and characterization of the antibody. For
purification of acetyl K873/K874 pRB antibodies we used a two-step protocol of
immunoaffinity column chromatography. Serum was first passed through a column that
contained acetyl K873/K874 coupled peptides and I eluted under low pH conditions to
isolate antibodies. To eliminate antibodies that detected non-acetylated or pRB, the
elution was passed through a second column that contained unmodified coupled peptide
(NPPKPL-K-K-LRFDIEG) and unbound flow through was collected for downstream use.
An ELISA was then carried out to test specificity of purified antibodies towards
acetylated peptide versus unmodified peptide. From this analysis, presented in Figure
3.4B, the purified antibody was able to recognize the acetylated peptide with at least 100
times higher affinity when compared to the unmodified peptide. Statistical analysis using
a T-test confirmed that this difference was significant. This result suggested to us that the
purified antibody was responsive to our antigen with a high order of specificity and
prompted us to further examine and characterize this antibody in regards to detection of
pRB K873/K874 acetylation.

59

Figure 3.3: Generation of an Antibody Against Acetylated pRB
A) Schematic diagram for the generation and purification of anti-acetyl K873/K874 pRB
antibodies. Serum was also used for indicated experiments where purification steps were
bypassed. B) Schematic of the two synthetic peptides used for antibody generation and
purification with mouse pRB sequence and residue numbers indicated. Synthetic
acetylation's on residues K873/K874 are indicated in purple. Residues highlighted in blue
are critical in the Protein phosphatase 1 docking site of pRB.
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Figure 3.4: ELISA Analysis Demonstrating Specificity of Anti-Acetyl K873/K874
pRB Antibody
ELISA experiments were carried out to analyze specificity of anti-acetyl K873/K874
pRB antibodies. Experiments were performed in triplicate on the same plate. A) Serum
was diluted and added to wells coated with the indicated peptides. Following addition of

Alkaline phosphatase secondary antibody and substrate, absorbance values were plotted
against serum dilution for each respective peptide or negative control. ** P<0.05 for
acetyl and wt peptides to negative control at half maximal absorbance dilution using a Ttest. B) Antibodies against acetyl K873/K873 pRB were and added to wells coated with
the indicated peptide or TBS as a negative control. Absorbance was determined for each
peptide and plotted against the indicated dilution. * P<0.05 for acetyl versus wt peptide at
half maximal absorbance dilution using a T-test. Error bars were plotted as standard
deviations.

61

3.3
Acetyl K873/K874 pRB Antibody Specifically
Detects Acetylated Recombinant pRB
Our initial characterization of the acetyl K873/K874 pRB antibody suggested specificity
towards acetylated peptide when compared to unmodified peptide, we next wanted to
examine more stringent conditions to further asses the specificity of our antibody. I set
out to carry out in vitro acetylation assays and assess specificity by the use of western
blotting. To begin these characterizations, I first set up in vitro acetylation assays using
recombinant GST-pRB LP as substrate of the Histone Acetyl Transferase (HAT) domain
of pCAF, which has been characterized in the past to acetylate pRB(Pickard et al., 2010).
These assays were carried out with either recombinant GST-pRB LP or non-specific
substrates GST or BSA. From the western blot presented in Figure 3.5A, we can see that
when probed with acetyl K873/K874 pRB antibody, we see a strong signal for acetylated
GST-pRB LP compared to GST-pRB LP lacking pCAF enzyme, as well as GST or BSA.
When this blot was probed with an acetyl-Lysine antibody as observed in Figure 3.5B,
we can see a specific signal for GST-pRB LP in the presence of pCAF. From these
observations, we suggest that our acetyl K873/K874 pRB antibody is able to specifically
recognize acetylated GST-pRB LP using in vitro acetylation. To further test the
specificity of our acetyl K873/K874 pRB antibody, specifically towards acetylation of
residues K873/K874 versus other potential acetylation sites on pRB a mutant of pRB was
tested in which K873 and K874 were changed to alanine. When in vitro acetylation
assays were carried out over a time course using this mutant of GST-pRB LP as shown in
Figure 3.6, and then probed with acetyl-K873/K874 pRB antibody, we observed that
wildtype GST-pRB LP shows a specific signal when compared to both unmodified
wildtype GST-pRB LP as well as GST-pRB LP K873/K874A. When probed with an
acetyl-lysine antibody, no discernible signal could be observed for any of the reaction
conditions. Furthermore, when a Coomassie loading control was examined for the
indicated reactions, it was observed that similar loading was achieved for the three
different GST-pRB LP reaction groups, and although no signal was seen with the acetyllysine antibody western blot, the positive signal seen from the acetyl K873/K874 pRB
blot suggests that the experimental conditions were successful. Thus it can be concluded
that pRB acetylation on K873/K874 can be specifically detected by our acetyl-
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Figure 3.5: Anti-Acetyl-pRB Antibody Specifically Detects Modified GST-pRB LP
3 µg of recombinant GST-pRB LP (aa 379-928) was used as a substrate in an in vitro
acetylation assay with recombinant pCAF. BSA and GST were used as non-specific
substrates
and reactions
withoutGST-pRB
pCAF were
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Figure 3.6: Anti-Acetyl K873/K874 pRB Antibody Specifically Detects Modified
GST-pRB LP
3 µg of recombinant GST-pRB LP or K873/K874A GST-pRB LP were used for in vitro
acetylation by recombinant pCAF. GST was used as non-specific substrate and reactions
without pCAF were used to gauge specificity of antibodies towards modified substrate.
Samples were incubated for the above indicated times and then subjected to analysis by
SDS-PAGE and western blotting. The top image is of a western blot using anti-acetyl
K873/K874 pRB antibody, with the lower image showing Coomassie staining of GSTpRB LP protein loading for each respective sample. The middle image is a western blot
using anti-acetyl-lysine-antibody. Bands indicated with an * correspond to GST-pRB LP.
N=1 for both blots and Coomassie gel presented in this figure.
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K873/K874 antibody and that this antibody demonstrates sufficient specificity with
regards to the in vitro assays carried out to undertake further analysis of pRB acetylation
using this reagent.

3.4
CDK Phosphorylation of pRB May Be Affected by
pRB K873/K874 Acetylation
To further characterize pRB acetylation on lysine residues 873 and 874, I set out to
examine CDK kinase activity towards pRB which had been acetylated on these residues
through in vitro assays. Previous work suggests that acetylation of pRB at these residues
disrupts CDK phosphorylation of pRB, though many of these studies are based on
molecular modeling of the pRB C-terminus using X-ray crystallography structures (Chan
et al., 2001; Lowe et al., 2002; Wallace and Ball, 2004). Thus to assess CDK
phosphorylation of pRB, I carried out an in vitro kinase assay using CDK2. CDK2 was
immunoprecipitated from proliferating C33A cells, which are pRB null, and thus will not
offer endogenous pRB to confound our interpretation. Recombinant GST-pRB LP that
was either modified through the use of an in vitro acetylation assay or unmodified acted
as substrate for immunoprecipitated CDK2. As presented in Figure 3.7, we can see that
the ability of pRB to act as a CDK2 substrate seemed to be unaffected by the presence of
K873/K874 acetylation compared to unmodified pRB when compared to levels of
recombinant GST-pRB LP present in each lane. From these observations, we questioned
whether the population of GST-pRB LP that was acetylated was substantial enough to
mask the effects of non-acetylated pRB, due to the high sensitivity of detection of
radiolabelled substrate. With this possible caveat, I then set out to further test this using a
more selective approach. To carry out this more selective approach, I established an
immune-purification approach for isolating K873/K874 acetylated GST-pRB LP from the
population, the outline for this experiment is detailed in Figure 3.8. For this protocol, I
used either the K873/K873 acetyl pRB antibody or M136 antibody, which had been
purified against the unmodified peptide of the K873/K874 antibody. This allowed for us
to normalize for epitope efficiency in regards to immunoprecipitation between the two
respective antibodies. Following immunoprecipitation of the indicated substrates, CDK2
kinase assays were performed to compare the incorporation of γ-32P-ATP between
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observed that the band intensity for incorporation of γ-32P-ATP for the unmodified GSTpurified K873/K874 acetylated GST-pRB LP and unmodified GST-pRB LP. From
observation of Fig. 3.9A, we noticed that the acetylated K873/K874 GST-pRB LP that
was immunopurified exhibited less incorporation of γ-32P-ATP compared to unmodified
wildtype GST-pRB LP. When densitometry was performed on the autoradiogram, I
observed that the band intensity for incorporation of γ-32P-ATP for the unmodified GSTpRB LP was reduced compared to the acetylated GST-pRB LP. When the loading of the
samples was analyzed using Western blot analysis with the RB4.1 antibody, we can see
from Fig. 3.9B that both antibodies were able to pull down similar levels of either acetyl
K873/K874 pRB or unmodified pRB, suggesting the differences in CDK2
phosphorylation we observed could be attributed to the acetylation of K873 and K874.
From these experiments, we have evidence to suggest that acetylation of these two
indicated lysine residues in pRB may in fact regulate the ability of pRB to serve as a
CDK2 substrate in vitro.

3.5
Acetylation of pRB at K873 and K874 is Unable to
be Detected In Vivo
The in vitro results presented earlier in this chapter suggested that the antibody that we
had developed for acetyl K873/K874 pRB was a highly specific reagent that could be
used to examine the occurrence of these post-translational modifications in cells. To
determine whether pRB could be acetylated on K873/K874 in cells that were
asynchronously proliferating, I carried out immunoprecipitations for pRB from two
different cell types and performed western blot analysis on IP fractions using acetyl
K873/K874 pRB antibody. As demonstrated in Figure 3.10B, when probed with our
antibody we were unable to detect the presence of acetyl K873/K874 pRB. This is in
accordance with Western blot analysis presented in Figure 3.10A, which demonstrated
the IP efficiency for pRB. Furthermore both blots were run with a positive standard,
which was GST-pRB LP which had been acetylated using an in vitro acetylation assay.
The positive signal from this standard as shown in Figure 3.10B demonstrates that our
antibody was able to detect modified pRB, suggesting no technical reasons for the lack of
bands corresponding to acetyl K873/K874 in the IP lanes.
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Figure 3.7: CDK Phosphorylation of Acetylated GST-pRB LP
Kinase activity of CDK2 was determined against acetylated and unmodified GST-pRB
LP substrates as described in the previous figure. 3 µg of GST-pRB LP substrates were
32

exposed to immunoprecipitated CDK2 along with γ- P-ATP at 30°C for 20 mins.
Samples were then resolved on a polyacrylamide gel. Phosphate incorporation was
determined by autoradiography and relative protein levels are shown by Coomassie
staining. N=1 for the autoradiograph and Coomassie for those presented in this figure.
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Figure 3.8: Schematic of Immunopurified Acetyl K873/K874-pRB Substrate Kinase
Assay
Procedure used to immunopurifiy GST-pRB LP substrate that had undergone acetylation
and its use as a substrate in a CDK2 kinase assay

68

Figure 3.9: Acetylation of pRB Inhibits CDK Phosphorylation
A) Kinase activity of CDK2 was determined against acetylated and unmodified GSTpRB LP substrates as described in the previous figure. Substrates were exposed to
32

immunoprecipitated CDK2 along with γ- P-ATP at 30°C for 20 minutes. Samples were
then resolved by SDS-PAGE, a representative radiogram is shown with densitometric
quantification below. B) Immunoprecipitation efficiency of acetylated and unmodified
GST-pRB LP substrates by their respective antibodies was determined by Western
blotting. Equal volumes were analyzed by SDS-PAGE followed by Western pRB with an
independent antibody. N=1 for experimental data presented in this figure.
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From these results, we next wanted to examine conditions from the literature that have
been suggested to increase the accumulation of acetyl K873/K874 pRB. One of the
conditions that have been suggested from prior work is double stranded DNA breaks
induced by etoposide treatment (Carnevale et al., 2012; Markham et al., 2006). To
examine DNA damage induced pRB acetylation of K873/K874, I treated ML1 cells
with100 µM of Etoposide for 8 hours and performed GST-E7 pulldowns to enrich for
pRB from these cells. Following GST-E7 pulldowns, Western blot analysis on the
pulldown fractions of Etoposide treated and DMSO treated cells was performed and
presented in Figure 3.11A. We observed that treatment of ML1 cells with Etoposide lead
to an activation of p53 signaling as demonstrated by increased pS15-p53, and thus an
activation of DNA damage signaling. From Western blot analysis presented in Figure
3.11B, we can observe that GST-E7 pulldown from these cells was sufficiently able to
enrich for endogenous pRB. When pulldown fractions were then probed with the acetyl
K873/K874 pRB antibody, we observed no detectable signal from either the input or
pulldown fractions, suggesting that acetyl K873/K874 pRB was in fact not present as
shown in Figure 3.11C. Further, through Western blot analysis using an acetyl-lysine
antibody as depicted in Figure 3.11D, we observed a band in the input fraction that could
correspond to pRB but this band was not replicated in the pulldown fraction, suggesting
this band does not correspond to acetyl-pRB and agrees with the results demonstrated in
Figure 3.11C. From these experiments, we can suggest that acetyl K873/K874 pRB is not
enriched for in cells that have undergone DNA double strand breaks.
Based on previous work in our lab, it has been suggested that upon DNA double
strand breaks induced by Etoposide, pRB and E2F1 complexes are formed that include
acetylated pRB. I treated U2OS cells with 100 µM Etoposide for 8 hours and performed
an immunoprecipitation for E2F1. Presented in top portion of Figure 3.12 is Western blot
analysis for E2F1 demonstrating that the IP was successful while in the bottom portion of
Figure 3.12 is Western blot analysis using acetyl K873/K874 pRB antibody. From this
analysis, we can see that there is no significant enrichment of acetyl K873/K874 signal
over IgG in either treatment group. This result suggests that under a scenario of DNA
damage, acetyl K873/K874 pRB is not associating with a pRB bound E2F1 population.
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Figure 3.10: Unable to Detect Ac-pRB in Asynchronous Cells
U2OS and HEK293 nuclear extract was harvested from asynchronous proliferating cells.
Immunoprecipitations were performed for pRB with 2 mg of extract from both sets and
corresponding samples were resolved by SDS-PAGE with indicated western blots
performed. 200 µg of nuclear extract was taken and loaded as input while 300 ng of AcGST-pRB LP was used as a positive control. A) A western blot against pRB using an
antibody independent of the immunoprecipitation. B) Western blot with acetyl
K873/K874 pRB antibody. N =1 for the blots presented in this figure.
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Figure 3.11: Unable to Detect Ac-K873/K874 pRB Following DNA Damage
GST pulldown binding experiment using recombinant GST-E7 with 2 mg of nuclear
extract from ML1 cells treated with either 100 µM Etoposide (Etop) for 8 hrs or DMSO
vehicle as control. 200 µg of nuclear extract from either DMSO or Etop were used as the
corresponding input. A) Western blot for pS15 -p53 to demonstrate that Etoposide
treatment lead to an increase in DNA damage signaling. Bands indicated with the *
correspond to pS15 p53. B) Western blot for pRB to demonstrate that the recombinant
GST-E7 was able to successfully pulldown pRB from these cells and to demonstrate
similar loading between treatment groups. C) Western blot for ac K873/K874-pRB using
purified antibody from both treatment groups. D) Western Blot for acetyl lysine from
both treatment groups. N =1 for all the blots presented in this figure.
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Figure 3.12: Unable to Detect Ac-K873/K874 pRB Binding to E2F1
E2F1 immunoprecipitations were performed from U2OS cells treated with 100 µM
etoposide for 8 hrs or DMSO vehicle control. 2 mg of nuclear extract were collected

from each treatment group with 200 µg of extract used for input. A) Western blot for
E2F1 confirming immunoprecipitation from both treatment groups. B) Western blot for
ac-K873/K874-pRB is performed on each immunoprecipitated fraction using purified
antibody. N= 1 for both blots presented in this figure.
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Chapter 4

4

The Rb1ΔPP1 Mouse
4.1
Generation of Rb1ΔPP1 Gene Targeted Mouse
Model

Previous work in our lab has identified a specific mutation in the pRB C-terminus,
identified as R876F/ F877R, which is able to disrupt Protein Phosphatase 1 binding while
retaining CDK2 binding in the analogous region (Hirschi et al., 2010). This mutation
allows for the study of PP1 binding in the pRB C-terminus and its direct function in
regards to pRB while still maintaining proper CDK phosphorylation of pRB. To study
this potential means of phosphorylation regulation of pRB, I set out to create a gene
targeted mouse which incorporated the analogous mouse mutation R869F/F870R into the
mouse Rb1 gene and we designate this allele of Rb1 the Rb1ΔPP1 mutation. As presented
in the schematic in Figure 4.1B, this mutation in the Rb1 allele would potentially allow
for a mutant of pRb that would discretely disrupt PP1 mediated activation of pRB while
maintaining CDK phosphorylation. This theoretically could alter the equilibrium between
these states and force pRb towards a more hyperphosphorylated form in this gene
targeted mouse model.
To generate this mouse model for Rb1ΔPP1, detailed in Figure 4.1A is a schematic
detailing the work flow associated with generating this mouse model. The first step was
the creation of the targeting vector to allow for homologous recombination of our desired
mutation into the mouse Rb1 locus. We used a previous method to target a nearby region
in Rb1 as a basis for our strategy, which is summarized in Figure 4.2 detailing the
Rb1ΔPP1 targeting construct in relation to the Rb1 locus (Chau et al., 2002). A 12 kb
portion of the 3‟ end of the Rb1 allele was used as a means to facilitate homologous
recombination, allowing for integration of our mutation into the Rb1 gene. The
R869F/F870R mutation was inserted into exon 25 along with an EcoRI restriction
enzyme digest site in intron 24. The addition of this EcoRI site allows for differentiation
between targeted alleles and wildtype alleles when performing the Southern blot
screening. A PGK-Neo cassette flanked by LoxP sites was then inserted into intron 25 to
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allow for neomycin selection of mouse embryonic stem cells with integration of the
targeting vector into the mouse genome. The completed targeting vector was linearized
using a NotI restriction digest and provided to the London Regional Transgenic and Gene
Targeting facility where this construct was electroporated into mouse embryonic stem
cells with clonal expansion of the neomycin resistant cells.

4.2
Southern Blot Screening Lead to a Small Selection
of Potential Targeted Clones
To determine whether mESC clones had properly incorporated the Rb1ΔPP1 targeting
construct into the mouse genome, I performed Southern Blot screening to determine
proper targeting of the Rb1 locus. 180 mESC clones which had been expanded and
selected in neomycin were used for Southern blot screening, with genomic DNA isolated
from each clone. Genomic DNA for each clone was digested using the HindIII restriction
enzyme and electrophoresed on an agarose gel. Following transfer onto a nitrocellulose
membrane, a radiolabelled probe for Exon 24 of the mouse Rb1 gene was used as a
probe. Membranes were then washed and exposed for autoradiography and images were
developed. Presented in Figure 4.3A is a representative blot of screening using the Exon
24 probe with the HindIII restriction digest and from this blot we can observe that the
clones labeled 1-5F and 1-2D both show a doublet of bands. Clone 1-2D shows the
expected bands at 6 kb and 9 kb indicating a properly targeted clone. Clone 1-5F had an
observable pair of bands, though it appears that the bands were at higher than the
expected size. This aberrant size of the observable doublet could have been due to
unusual migration of digested DNA due to contaminates in the DNA, such as excess
salts. Further screening was carried out and as shown in Figure 4.3B, clone 4-4A when
digested with HindIII and subjected to Southern blot analysis with the Exon 24 probe,
produced an observable doublet of bands at 6 and 9 kb. This doublet pattern again is
representative of the correct size distribution expected from a correctly targeted Rb1
locus. From this comprehensive screening of 180 mESC clones, two clones offered
potential as correctly targeted clones. These candidate clones, along with others, were
selected to be regrown from cellular stocks to be subjected to more rigorous screening to
confirm the presence of the Rb1ΔPP1 allele.
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Figure 4.1: The Rb1

ΔPP1

Mutation and Schematic of Targeting for Rb1

ΔPP1

Gene

Targeted Mice
A) General schematic for the process of generating a gene ES line that would contain the
ΔPP1 mutation in the Rb1 gene. B) Schematic depicting the potential molecular
consequence of this mutation on the pRb protein.
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Figure 4.2: Schematic of Targeting for Rb1

ΔPP1

Mutation in the Rb1 Locus

Following electroporation of 129 ES cells with the targeting construct, clones were
screened by Southern blotting. Initial screening of ES clones was carried out using a
HindIII digestion to give a wildtype fragment of 6 kb versus 9 kb for targeted alleles. BBamHI, H-HindIII, R-EcoRI, S-SacI, 25*-Exon 25 with ΔPP1 mutation, 25- Exon 25,
26-Exon 26, 27- Exon 27
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Figure 4.3: Screening of mESCs with Southern Blotting for Incorporation of the
ΔPP1

Rb1

into the Rb1 Locus

Incorporation of the ΔPP1 mutation into the Rb1 locus, through homologous
recombination, was determined by Southern blotting. A) A representative image shows
southern blot screening using the Exon 24 probe and a HindIII digest. B) A
representative image shows Southern blot screening using the Exon 24 probe and a
HindIII digest. N =1 for both Southern blots presented in this figure.
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4.3
Confirmation Screening of Candidate mESC
Clones Showed No Correctly Targeted Clones
To ensure that our candidate mESC clones were in fact targeted and usable for blastocyst
injections, a more rigorous round of screening was performed to confirm our results from
the mass screenings. The indicated mESC clones were regrown in neomycin selection
medium and genomic DNA was extracted. Southern blot screening was carried out as a
means to confirm proper single integration of the targeting construct into the mouse Rb1
locus. Southern blots were performed using genomic DNA digested with HindIII
restriction enzyme and probed using a radiolabeled probe corresponding to the neomycin
resistance cassette. From this screening, we observed that the candidate clones showed
single integration of the neomycin cassette into the mouse genome (Figure 4.4). With this
result, I then set out to carry out the confirmation screening using the Exon 24 probe with
the HindIII digest and a EcoRI digest. As shown in Figure 4.5A, when the HindIII digest
was carried out and the radiolabelled Exon 24 probe was used in Southern Blot screening
of the three indicated mESC clones, it can be observed that all three clones showed the
presence of only the 6 kb band, which corresponds to the wildtype Rb1 locus. In
coordination with this screening, the EcoRI digest was performed and Southern blot
analysis was performed using the Exon 24 probe which is presented in Figure 4.5B. From
analysis of this Southern blot we observed that all three clones displayed a band at
approximately 20 kb. This 20 kb fragment corresponds to the wildtype Rb1 locus,
whereas a correctly targeted clone would have a 9 kb fragment when subjected to
Southern blotting with the Exon 24 probe and the EcoRI digestion. From these results, we
can conclude that of the three candidate clones isolated from our initial mass screening of
180 mESC clones, none were in fact correctly targeted when subjected to this second
round of more rigorous screening.
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Figure 4.4: Single Integration of the Neomycin Selection Cassette in Candidate
Clones
Single incorporation of the Neomycin selection cassette, through homologous
recombination, was determined by Southern blotting. Southern blotting using the
Neo probe following HindIII restriction digest of isolated genomic DNA was
performed for mESC clones which had been selected for confirmation screening.
Potential candidate clones are indicated. N = 1 for Southern blot screening
presented in this figure.
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Figure 4.5: Confirmation Southern Blot of Three Potentially Targeted mESC
Clones
Selected mESC clones were regrown and genomic DNA was isolated and southern blot
screening was carried out to determine if potential clones were correctly targeted. A) The
indicated mESC clones were digested with HindIII and southern blot was performed
using the exon 24 probe. B) The indicated mESC clones were also digested with EcoR1
and southern blot was performed using the exon 24 probe. N = 1 for Southern blot
screens performed in this figure.
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5

Discussion

5.1 Summary of Findings
The retinoblastoma protein has been extensively studied in regards to post-translational
modification primarily through phosphorylation by CDKs. More recent work has begun
to emerge in the field that has begun to focus on other post-translational modifications of
pRB and the potential for added complexity in regards to the multitude of pRB functions.
One potential means for further regulation of pRB function may lay in acetylation in the
C-terminus of pRB at lysine residues 873 and 874(Chan et al., 2001). These particular
lysine residues lie directly in a binding domain for both Cyclin/CDKs and PP1(Hirschi et
al., 2010). I hypothesized that the regulation of pRB dephosphorylation is critical in
regulating pRB function and activity and that acetylation of lysines 873 and 874 in the
pRB C-terminus may play a role in the regulation of pRB dephosphorylation. From the
work presented in this thesis, I have shown the generation of an acetyl K873/K874 pRB
antibody which specifically detects acetylation of K873/K874 in the pRB C-terminus
through the use of in vitro assays. Through the use of these assays I was able to
demonstrate that CDK2 kinase activity towards pRB, which had been acetylated at
K873/K874, was in fact reduced when compared to unmodified pRB. In vivo assays that
were used to isolate conditions where acetyl K873/K874 pRB has been suggested to
occur, such as DNA damage, were then assessed to act as positive control conditions for
future work(Carnevale et al., 2012; Markham et al., 2006). From the results presented in
Figures 3.9-3.11, we interpret that with our antibody, we were unable to detect acetylated
K873/K874 pRB through enrichment of pRB or through association with E2F1 under
either asynchronous or DNA damage through double stranded breaks.
Regulation of phosphorylation of the retinoblastoma protein has largely been
studied by the means of regulating Cyclin/CDK phosphorylation of pRB. Recent work
from our lab though has uncovered an overlapping CDK and PP1 binding domain in the
C-terminus of pRB. This overlapping binding site offers a novel and compelling means of
discrete regulation of pRB, by the means of competitive access between the respective
kinase and phosphatase. From previous work in our lab, a mutation in this binding site
was uncovered that was able to specifically disrupt PP1 binding to pRB without
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disrupting CDK binding to the pRB C-terminus. This mutation in the pRB C-terminus is
distinguished as the pRBΔPP1 mutation and allows for discrete study of pRB
dephosphorylation uncoupled from CDK phosphorylation. In this thesis, I detailed work
outlining the construction and generation of a targeting construct that would allow for
gene targeting of the mouse Rb1 locus with the pRbΔPP1 mutation. As presented and
shown in this work, through Southern blot screening, we were able to see clones that
appeared to be targeted but through screening confirmation using regrown mESC clones
and southern blotting, these clones appeared to lose the targeted allele.
As mentioned previously in my introduction, the study of pRB dephosphorylation
has been characterized previously in the literature but to a much lesser extent than CDK
phosphorylation of pRB. This work though has typically lacked insights into how
phosphatases are specifically recruited to act on pRB, in particular cellular contexts of
stress distinctively highlight our lack of understanding into the mechanistic basis of pRB
dephosphorylation. The work highlighted in this thesis is a novel approach in regards to
studying pRB with respect to dephosphorylation, particularly through a study of posttranslational modification and the PP1/CDK binding site within pRB. This study helps us
to gain further insight into the process of dephosphorylation, and highlights the
regulatory elements such as the PP1 C-terminal docking site and pRB acetylation that
may play an important role in this process.

5.2

Acetylation of pRB

Our observations in respect to the lack of pRB acetylation at K873 and K874 in vivo
through western blotting using our anti-acetyl K873/K874 pRB antibody was a stark
contrast to the reported literature findings. A critical examination of the body of literature
with respect to pRB acetylation at K873 and K874 though may provide insights in
regards to our observations. Previous work including (Chan et al., 2001) regarding
acetylation of pRB identified lysine residues 873 and 874 as acetylation sites through
similar in vitro acetylation assays. The observations noted in Chapter 3 of this thesis are
similar to those documented by Chan and colleagues, including the need to selectively
purify acetylated pRB substrate to demonstrate biochemical effects such as reduced CDK
phosphorylation. Interestingly from this work, experiments confirming that these sites
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were indeed present in vitro are lacking substantial in vivo verifcation to confirm that
K873 and K874 are the acetylation sites responsible for the observed effects. Most in vivo
experiments used to confirm the presence of these modifications are reliant on the use of
immunoprecipitations and western blotting using pan-acetyl-lysine antibodies, similar to
those presented earlier in this work. Anecdotally, these antibodies appear to be
challenging to present reliable data that can be easily interpreted by the user, which can
be noted from discrepancies of Western blots presented in Figure 3.5B and Figure 3.6
with regards to western blots with anti-acetyl lysine antibodies. Most of the previously
discussed work in the literature is also limited to transfection based experiments
involving isolation of tagged pRB populations and western blotting with acetyl lysine
antibodies. These experiments highlighted from previous reports raise the questions of
how representative these experimental conditions are to more physiological experiments.
As discussed in the introduction, various proteomic approaches have highlighted multiple
acetylation sites throughout pRB. These acetylation sites in pRB could have been falsely
attributed to acetylation at K873 and K874 primarily due to most experiments having to
rely on acetyl-lysine antibodies for detection of K873/K874 acetylation. This ambiguity
regarding the exact conditions of K873/K874 acetylation leads to the obvious question of
whether the conditions we attempted to observe this set of modifications, specifically
DNA damage signalling induced by double stranded breaks, were in fact the best choice
to find this set of modifications. While the work of Markham and colleagues (Markham
et al., 2006) suggest that pRB under DNA damage is acetylated on K873/K874 and
promotes association with E2F, other work has shown more generalized results attributed
to acetyl lysine blots or association with acetyltranferases including p/CAF (Carnevale et
al., 2012; Ianari et al., 2004; Ianari et al., 2009). The later reports again leave open the
possibility that in fact acetylation of pRB observed under DNA damage scenarios could
be attributed to other sites in pRB or in fact other proteins involved in large protein
complexes. A further layer of complexity regarding K873/K874 acetylation lies in the
lack of proteomic evidence for K873 acetylation under the admittedly limited conditions
investigated, as well as these studies showing no occurrence of both K873/K874 on pRB
peptides analyzed. This ambiguity that underlines the prior literature draws into question
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whether K873/K874 acetylation is in fact present under the conditions of DNA damage
that we examined or in fact whether both lysine residues are in fact acetylated in vivo.

5.3
Lack of K873/K874 Acetylation of pRB In Vivo
Under DNA Damage with Acetyl-K873/K874 Antibodies
The lack of commercial reagents towards K873/K874 acetylation has further hampered
their study, with present knowledge suggesting one other group attempting to generate
any type of antibody against this set of modifications. Prior work by Markham and
colleagues (Markham et al., 2006) demonstrated the production of a similar antibody
against this modification, though work using this antibody is limited to
immunofluorescence and western blotting with mixed results. Our hypothesis that pRB
phosphorylation could be regulated through the acetylation of K873 and K874 through
acetylation motivated us to generate a specific antibody against the combination of
acetylated K873/K874. Through the in vitro work presented to characterize our
antibodies against acetylated K873/K874 demonstrated specificity for the tandem
acetylation by means of Western blotting, we were unable to detect acetylation with our
in vivo experiments. One explanation for this is technical limitations of the presented
experiments in this work, either through scale of the experiment with respect to amounts
of material used or limits of detection of substrate in regards to western blotting. Ideally,
future experiments involving mass spectrometry using cells that have been subjected to
DNA damage would be the best scenario to test for the presence of K873/K874 pRB
acetylation and whether these modifications occur in tandem.
The lack of evidence for pRB acetylation at K873 through proteomic approaches
compared to the more targeted approaches to studying post-translational modifications
creates a conflict of whether in fact K873 is acetylated in physiological paradigms.
Further analysis of K873 presents literature that acts to further confound this issue, as
pRB has been shown previously to be methylated on K873 and not on K874(Munro et al.,
2010). While DNA damage conditions are not specifically analyzed in this report for
K873 methylation, the author‟s report that methylation at this site seems to be a
requirement of proper in vitro myoblast differentiation and senescence of cells. The
requirement of K873 methylation in myoblast differentiation mimics a prior report
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(Nguyen et al., 2004) that states K873/K874 acetylation is required for myoblast
differentiation. With similar conditions attributed to both modifications, this prompts us
to speculate whether prior results of K873/K874 acetylation observed under DNA
damage could in fact be K873 methylation with K874 acetylation. Thus the possibilities
that under DNA damage, pRB could be acetylated at only K873, methylated at K873 or a
combination of both modifications could be present on pRB in this scenario. The
circumstances where different single site modifications or combinations of acetylation
present obvious issues in regards to our generated antibody. At this time, we are unable to
rule out whether our acetyl K873/K874 pRB antibody is able to detect instances where
only K874 is acetylated, K873 is methylated or the possible instance where K873 is
methylated and K874 is acetylated. To further elucidate the specificity of our generated
antibody against these specific combinations of post-translational modifications, one
could envision performing similar ELISA experiments highlighted in Figure 3.5, with a
range of synthetically modified peptides baring the various combination of modifications
to test whether our antibody is able to recognize these epitopes. The generation of a panel
of antibodies against the different combination of modifications and performing similar
experiments against DNA damaged cells would be worthwhile to further explore whether
these combination of modifications are responsible for the previously reported studies.
The work outlined in this thesis helps us to further build an understanding of the intricate
nature of post-translational modifications in regards to pRB. While historically pRB has
been regarded for the general system of widespread phosphorylation by CDKs, even this
paradigm has begun to be challenged. As summarized in recent review articles, work in
the field has led to the emergence of a host of post-translational modifications of pRB
that could act in concert to regulate the multitude of pRB functions (Macdonald and
Dick, 2012; Munro et al., 2012). With the emergence of better analytical techniques and
proteomic approaches to study post-translational modifications of proteins, we are
beginning to see the higher order complexity involved in managing and regulating the
wide cascade of post-translational modifications. This work begins to outline acetylation
of pRB at K873 and K874 in the pRB C-terminus and the potential for a much more
complicated system of post-translational modifications that may be context dependent.
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5.4
Attempted Creation of the Rb1ΔPP1 Gene
Targeted Mouse
In chapter four of this thesis, I detailed work to produce a targeting construct to generate
gene targeted mice which harboured a mutation in pRB which we deem the ΔPP1
mutation. This mutation in pRB has been previously characterized in our lab to disrupt
Protein Phosphatase 1 binding in the C-terminus of pRB in a region where Cyclin/CDKs
have been shown to bind pRB without disrupting Cyclin/CDK binding (Hirschi et al.,
2010). This mutation presented us with a unique means of studying the process and
regulation of pRB dephosphorylation in an in vivo model system. Much of the work to
date characterizing pRB dephosphorylation in vivo has relied on drug treatments targeting
phosphatases, leaving the direct consequences of deregulated pRB dephosphorylation
difficult to interpret due to the wide swath of cellular functions attributed to protein
phosphatases (Moorhead et al., 2007). Thus our approach of generating a gene targeted
mouse disrupting PP1 binding to pRB would allow us to study the consequences of pRB
dephosphorylation in isolation with respect to other PP1 cellular functions
Through construction of our Rb1ΔPP1 targeting construct we envisioned the ability
to isolate mESC clones which harboured our mutant allele of pRB. The strategy used to
build our targeting construct was based off work in the Wang lab, which generated a gene
targeted mouse targeting residues in exon 25, similar to our mutation (Borges et al., 2005;
Chau et al., 2002). This gene targeted mouse, along with pRB gene targeted mice
established in our lab had no issues with viability and are able to create viable mice, thus
we hypothesized there would be no issues with the allele recombination and that these
mice would be viable(Cecchini et al., 2014; Isaac et al., 2006). Through Southern blot
analysis of mESC clones electroporated with our targeting construct, our initial screening
identified two candidate clones which appeared to have proper targeting of the Rb1 gene.
When our confirmation screening was carried out, surprisingly we found that our three
clones appeared to not have the targeted allele.
These results were surprising to us as we had expected little to no issue with
generating the targeted mESC cells based on prior experiences in our lab and as well as
work done by the Wang group, as outlined in the preceding paragraph. While we cannot
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provide definitive reasons for the odd behaviour exhibited through our work targeting the
PP1 binding site within pRB, I offer up some speculative and circumstantial reasoning
why this phenomenon was observed in our hands. Recent literature that emerged during
screening of our mESC clones highlights the potential regulatory role of pRB in stem
cells. From this work, though mostly done in hESCs, presented the idea that inactivation
of pRB forces hESCs to either undergo differentiation or have apoptotic programs
activated. Furthermore, the authors suggest that a pool of hypophosphorylated or active
pRB is maintained, even in systems where hESCs are still proliferating and maintaining
stem-like qualities (Conklin et al., 2012; Sage, 2012). The introduction of our pRBΔPP1
mutation into mESC cells, with the effect of disrupting the dephosphorylation of pRB and
subsequent activation may have a much larger role in this cell population than initially
thought of by disrupting the balance of pRB activity required in these cells. The
disruption of this small pool of activated pRB may have the unintended effect of forcing
these cells to differentiate or in fact promoting apoptosis in these cells, hindering our
ability to clonally expand and isolate correctly targeted cells.
As previously mentioned above, the targeting strategy for our allele was adopted
from the method used by the Wang lab to develop mice which removed a caspase
cleavage site in this region of pRB(Borges et al., 2005; Chau et al., 2002). One detail that
initially was not considered when creating this construct was the orientation of the
neomycin cassette used for selection of targeted cells in our system. The method used by
the Wang lab when constructing their construct left the Neo cassette in the same
orientation as the Rb1 gene, allowing both the pRb transcript and the Neo transcript. This
production of the pRb transcript and subsequent protein product allows for the active
expression of our mutant protein in the mESC cells, whereas the alternative orientation of
the Neo cassette would primarily have Neo transcript produced without mutant pRb
transcript. Thus in our system, pRbΔPP1 protein could be expressed in our mESC cells
during initial selection. The expression of the mutant pRb in this context could easily be
envisioned to create a disruption in the balance of inactivated hyperphosphorylated pRB
versus activated hypophosphorylated pRB in these mESCs that were in fact correctly
targeted. This imbalance could be predicted to lead to either cells being selected for
differentiation or for apoptosis. This would mirror the effects we observed where as we
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continued to passage the potentially targeted mESC clones, we lost the targeted allele
when genomic DNA was analyzed using Southern blots. Thus we could speculate that
this loss of the targeted allele could be attributed to positively targeted cells undergoing
differentiation or apoptosis, and thus being lost over subsequent passages.
From this speculation into our failed targeting of the pRbΔPP1 mutant, some
identifiable caveats to our targeting have potentially emerged that could be mitigated to
some degree. One potential means of allowing for easier targeting would be to reverse the
orientation of the Neomycin cassette, thus restricting the ability for our mutant allele to
be transcribed until later stages of the process, where targeted mice are bred with mice
expressing Cre recombinase which cleaves the LoxP elements to remove the Neo
cassette.
This work detailing our attempts to generate the pRbΔPP1 mouse model to study
targeted disruption of PP1 binding to pRb and potentially deregulating pRb
dephosphorylation offers a potentially exciting insight into this relatively understudied
process in regards to pRb function. From our results, it may appear that regulation of PP1
binding in pRb by means of the C-terminal binding site within pRB may be critical to
mESC and potentially all stem like cells.

5.5

Conclusions

The work presented in this thesis help to begin to elucidate potential means of regulating
pRB dephosphorylation, which is a critical process in activating pRB, specifically in
scenarios such as DNA damage. The work presented here in regards to acetylation of
pRB at K873 and K874 which lie in a binding domain for PP1 with pRB, potentially
show a much greater complexity than initially reported. While the potential posttranslational modification regulatory system for the PP1 and CDK binding domain may
be more complicated than initially hypothesized, the need to understand regulation of this
site may be critical in regards to fully understanding PP1 mediated dephosphorylation of
pRB. From our work described within this thesis to generate a gene targeted mouse
model to examine disruption of the PP1 binding site in pRB, we have potentially isolated
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a critical means of controlling pRb dephosphorylation and activation that when perturbed,
may have deleterious effects in mESC stem cells.

5.6

References

Borges, H.L., Bird, J., Wasson, K., Cardiff, R.D., Varki, N., Eckmann, L., and Wang,
J.Y. (2005). Tumor promotion by caspase-resistant retinoblastoma protein. Proc Natl
Acad Sci U S A 102, 15587-15592.
Carnevale, J., Palander, O., Seifried, L.A., and Dick, F.A. (2012). DNA damage signals
through differentially modified E2F1 molecules to induce apoptosis. Mol Cell Biol 32,
900-912.
Cecchini, M.J., Thwaites, M.J., Talluri, S., MacDonald, J.I., Passos, D.T., Chong, J.L.,
Cantalupo, P., Stafford, P.M., Saenz-Robles, M.T., Francis, S.M., et al. (2014). A
retinoblastoma allele that is mutated at its common E2F interaction site inhibits cell
proliferation in gene-targeted mice. Mol Cell Biol 34, 2029-2045.
Chan, H.M., Krstic-Demonacos, M., Smith, L., Demonacos, C., and La Thangue, N.B.
(2001). Acetylation control of the retinoblastoma tumour-suppressor protein. Nat Cell
Biol 3, 667-674.
Chau, B.N., Borges, H.L., Chen, T.T., Masselli, A., Hunton, I.C., and Wang, J.Y. (2002).
Signal-dependent protection from apoptosis in mice expressing caspase-resistant Rb. Nat
Cell Biol 4, 757-765.
Conklin, J.F., Baker, J., and Sage, J. (2012). The RB family is required for the selfrenewal and survival of human embryonic stem cells. Nature communications 3, 1244.
Hirschi, A., Cecchini, M., Steinhardt, R.C., Schamber, M.R., Dick, F.A., and Rubin, S.M.
(2010). An overlapping kinase and phosphatase docking site regulates activity of the
retinoblastoma protein. Nat Struct Mol Biol 17, 1051-1057.

92

Ianari, A., Gallo, R., Palma, M., Alesse, E., and Gulino, A. (2004). Specific role for
p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response
to DNA damage. J Biol Chem 279, 30830-30835.
Ianari, A., Natale, T., Calo, E., Ferretti, E., Alesse, E., Screpanti, I., Haigis, K., Gulino,
A., and Lees, J.A. (2009). Proapoptotic function of the retinoblastoma tumor suppressor
protein. Cancer Cell 15, 184-194.
Isaac, C.E., Francis, S.M., Martens, A.L., Julian, L.M., Seifried, L.A., Erdmann, N.,
Binne, U.K., Harrington, L., Sicinski, P., Berube, N.G., et al. (2006). The retinoblastoma
protein regulates pericentric heterochromatin. Mol Cell Biol 26, 3659-3671.
Macdonald, J.I., and Dick, F.A. (2012). Posttranslational modifications of the
retinoblastoma tumor suppressor protein as determinants of function. Genes & cancer 3,
619-633.
Markham, D., Munro, S., Soloway, J., O'Connor, D.P., and La Thangue, N.B. (2006).
DNA-damage-responsive acetylation of pRb regulates binding to E2F-1. EMBO Rep 7,
192-198.
Moorhead, G.B., Trinkle-Mulcahy, L., and Ulke-Lemee, A. (2007). Emerging roles of
nuclear protein phosphatases. Nat Rev Mol Cell Biol 8, 234-244.
Munro, S., Carr, S.M., and La Thangue, N.B. (2012). Diversity within the pRb pathway:
is there a code of conduct? Oncogene.
Munro, S., Khaire, N., Inche, A., Carr, S., and La Thangue, N.B. (2010). Lysine
methylation regulates the pRb tumour suppressor protein. Oncogene 29, 2357-2367.
Nguyen, D.X., Baglia, L.A., Huang, S.M., Baker, C.M., and McCance, D.J. (2004).
Acetylation regulates the differentiation-specific functions of the retinoblastoma protein.
EMBO J 23, 1609-1618.
Sage, J. (2012). The retinoblastoma tumor suppressor and stem cell biology. Genes Dev
26, 1409-1420.

93

Curriculum Vitae
Name:

Paul Michael Stafford

Post-secondary
Education and
Degrees:

Queen‟s University
Kingston, Ontario, Canada
2007-2011.
Honors B.Sc with Subject of Specialization in Biochemistry
The University of Western Ontario
London, Ontario, Canada
2011-2014 M.Sc.
Supervisor: Dr. Fred Dick

Honours and
Awards:

Queen Elizabeth II Reach for the top Scholarship
2007
Queen‟s University
Dean‟s Honor List with Distinction
2007-2011
Western Graduate Student Research Award
University of Western Ontario
2011-2013

Related Work
Experience
Research Volunteer
Queen‟s University, Kingston, Ontario
May 2011- July 2011

Undergraduate Honors Research Project
Supervisor: Dr. Zongchao Jia & Dr. Vinay Singh
Biochemistry
Queen‟s University
Kingston, Ontario, Canada
September 2010- April 2011

94

Conferences and Presentations:
Second International RB Tumor Suppressor Meeting. Toronto,
Ontario. 2011
Stafford, P. Investigation of pRB regulation by post-translational
modifications. Lawson Health Research Day, University of
Western Ontario. 2014

Publications:
Cecchini MJ, Thwaites MJ, Talluri S, MacDonald JI, Passos DT,
Chong JL, Cantalupo P, Stafford PM, Sáenz-Robles MT, Francis
SM, Pipas JM, Leone G, Welch I, Dick FA. A retinoblastoma
allele that is mutated at its common E2F interaction site inhibits
cell proliferation in gene-targeted mice. (2014) Mol Cell Biol.
34(11): 2029-45.

